



(86) Date de dépôt PCT/PCT Filing Date: 2013/06/14
(87) Date publication PCT/PCT Publication Date: 2013/12/19
(45) Date de délivrance/Issue Date: 2021/08/31
(85) Entrée phase nationale/National Entry: 2014/12/05
(86) N° demande PCT/PCT Application No.: IB 2013/054888
(87) N° publication PCT/PCT Publication No.: 2013/186754
(30) Priorité/Priority: 2012/06/14 (EP12171941.3)

(51) Cl.Int./Int.Cl. *C12Q 1/689* (2018.01),
C07H 21/04 (2006.01), *C12Q 1/68* (2018.01),
C12Q 1/686 (2018.01)
(72) Inventeurs/Inventors:
FACH, PATRICK, FR;
DELANNOY, SABINE, FR;
BEUTIN, LOTHAR, DE
(73) Propriétaires/Owners:
AGENCE NATIONALE DE SECURITE SANITAIRE DE
L'ALIMENTATION, DE L'ENVIRONNEMENT ET DU
TRAVAIL, FR;
BUNDESINSTITUT FUR RISIKOBEWERTUNG, DE
(74) Agent: ROBIC

(54) Titre : METHODE DE DETECTION ET D'IDENTIFICATION DE L'INFECTION ENTERO-HEMORRAGIQUE A
ESCHERICHIA COLI

(54) Title: METHOD FOR DETECTING AND IDENTIFYING ENTEROHEMORRHAGIC ESCHERICHIA COLI.

(57) Abrégé/Abstract:

The invention relates to methods for predicting whether a sample contains enterohemorrhagic Escherichia coli (EHEC) of at least one of EHEC O157:[H7], O145:[H28], O103:[H2], O111 :[H8], O121 :[H19], O26: [H11], O45:[H2] or O104:[H4] serotypes, and for identifying said serotypes, through detection of gene espK in association with at least one of the genetic markers Z1151, Z1153, Z1154, Z1155, Z1156, Z6065, Z2098, ureD or espV and/or through detection of serotype-specific CRISPR sequences.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



WIPO | PCT



(10) International Publication Number
WO 2013/186754 A3

(43) International Publication Date
19 December 2013 (19.12.2013)

(51) International Patent Classification:
C12Q 1/68 (2006.01)

(21) International Application Number:
PCT/IB2013/054888

(22) International Filing Date:
14 June 2013 (14.06.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
12171941.3 14 June 2012 (14.06.2012) EP

(71) Applicant: **AGENCE NATIONALE DE SECURITE
SANITAIRE DE L'ALIMENTATION, DE L'EN-
VIRONNEMENT ET DU TRAVAIL** [FR/FR]; 27/31 av-
enue du Général Leclerc, F-94701 Maisons-alfort Cedex
(FR).

(72) Inventors: **FACH, Patrick**; 8 rue des Ormes, F-94200
Charenton Le Pont (FR). **DELANNOY, Sabine**; 1 rue
Victor Schoelcher, F-94230 Cachan (FR). **BEUTIN,
Lothar**; Am Schlachtensee 112, 14129 Berlin (DE).

(74) Agents: **VIALLE-PRESLES, Marie-José** et al.; Cabinet
Ores, 36 rue de St Pétersbourg, F-75008 Paris (FR).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,

BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:
20 February 2014

(54) Title: METHOD FOR DETECTING AND IDENTIFYING ENTEROHEMORRHAGIC ESCHERICHIA COLI

(57) Abstract: The invention relates to methods for predicting whether a sample contains enterohemorrhagic *Escherichia coli* (EHEC) of at least one of EHEC O157:[H7], O145:[H28], O103:[H2], O111 :[H8], O121 :[H19], O26: [H11], O45:[H2] or O104: [H4] serotypes, and for identifying said serotypes, through detection of gene espK in association with at least one of the genetic markers Z1151, Z1153, Z1154, Z1155, Z1156, Z6065, Z2098, ureD or espV and/or through detection of serotype-specific CRISPR sequences.



WO 2013/186754 A3

METHOD FOR DETECTING AND IDENTIFYING ENTEROHEMORRHAGIC *ESCHERICHIA COLI*.

The invention relates to the identification of Shiga toxin producing *E. coli* (STEC) that constitutes a severe risk for human health.

Shiga toxin-producing *Escherichia coli* (STEC) are a diverse group of *E. coli* belonging to over 400 *E. coli* O:H serotypes, some of which cause outbreaks and sporadic cases of foodborne illness ranging from diarrhoea to hemorrhagic colitis (HC) and the haemolytic uremic syndrome (HUS). According to their human pathogenicity the latter strains were also designated as enterohaemorrhagic *E. coli* (EHEC) (Levine 1987, Nataro and Kaper 1998). Numerous cases of HC and HUS have been attributed to EHEC serotype O157:H7 strains, but it has now been recognized that other serotypes of STEC belong to the EHEC group.

Hence, cumulative evidence from numerous countries indicates that up to 30-60% of human STEC infections are caused by non-O157 STEC and that as few as five to seven “priority” serotypes of STEC are implicated in outbreaks and sporadic cases of HC and HUS. These comprise serotypes O26:[H11], O45:[H2], O103:[H2], O111:[H8], O121:[H19], O145:[H28], O157:[H7] and their non-motile derivatives. In addition, an unusual strain of O104:[H4] has been associated with the largest outbreak of HC and HUS worldwide in 2011 (Scheutz et al., 2011; Frank et al., 2011; Struelens et al., 2011; Gault et al., 2011).

Consequently, many jurisdictions are considering implementation of food inspection programs to safeguard the public from these STEC strains with high virulence for humans. A rational approach for detection of these enterohaemorrhagic *E. coli* (EHEC) strains, as part of a risk-based food inspection program, requires clear definition of the hallmark characteristic of priority STEC (e.g. serogroup, serotypes, virulence and other markers) and effective approaches to detect these pathogenic STEC in foods. Detection of non-O157 EHEC is particularly challenging because, they have no specific characteristics that distinguish them from the large number of harmless commensal *E. coli* that share the same niches. A seropathotype classification has been proposed by Karmali et al. (2003) as a framework to identify the most important O-serogroups involved in food-borne outbreaks, based on severity of disease, frequency and association with outbreaks, but the reasons for the difference in virulence between the various STEC strains remains unclear. It is probable that this difference is due to differences in the pattern of virulence genes possessed by STEC strains and studies are needed to substantiate this and to identify appropriate molecular markers.

Techniques exist to determine the presence of a STEC contamination in a sample by for instance detecting the presence of the *stx1/stx2* genes and the *eae* gene located on the LEE (locus of enterocyte effacement), a locus that was first identified in enteropathogenic *E. coli* (EPEC). But the genetic basis of STEC pathogenicity is a lot more

complex than the presence or absence of one or both of these genes. In a complex sample (e.g. food, fecal, environmental samples), which may comprise a mixture of strains (e.g. a mix of STEC and EPEC strains), the presence of the *stx1/2* and *eae* genes is not indicative of the presence of an EHEC in this sample.

5 However, given that some STEC strains can cause very serious health problems in humans, the detection of a STEC strain in a food product leads to discarding said product, even though it is likely this STEC does not pose a threat to human health. This results in a large amount of wastage due to lack of discrimination between non-pathogenic STEC strains and EHEC strains.

10 It has been proposed to use, in addition to the *stx1/stx2* and *eae* markers, other genetic markers in order to selectively detect EHEC strains and differentiate them from non-pathogenic STEC strains. For instance, PCT WO 2011/018762 describes a method involving the combined detection of the genes *stx1*, *stx2*, *eae*, *nleB* and *espK* to predict the presence of EHEC in a sample.

15 However, there is still a need of reliable tests allowing a discriminative screening for the presence of EHEC, including non-O157 EHEC, and a specific detection of the EHEC serotypes involved, in particular in case of the "top seven" serotypes O26:[H11], O45:[H2], O103:[H2], O111:[H8], O121:[H19], O145:[H28], O157:[H7].

20 The inventors have now identified discriminative genetic markers associated with several STEC strains constituting a severe risk for human health. In particular, they have identified genetic markers located within CRISPRs (Clustered Regularly Interspaced Short Palindromic Repeats) sequences of EHEC strains with high virulence for humans.

25 CRISPRs are present within the genomes of many bacterial species, including *E. coli*. They consist of tandem sequences containing direct repeats of 21 to 47 bp long and separated by spacers of similar size. Spacers are derived from foreign nucleic acids, such as phages or plasmids, and it has been hypothesized that they can protect bacteria from subsequent infection by homologous phages and plasmids.

30 The inventors have sequenced the CRISPR loci of various EHEC strains which are associated with the world's most frequent clinical cases, and have identified different spacers that can be used for a specific identification of the EHEC serotypes O157:[H7], O145:[H28], O103:[H2], O111:[H8], O121:[H19], O45:[H2], O26:[H11], O104:[H4] and their non motile derivatives, which are responsible for the majority of EHEC infections in humans.

35 Therefore, an object of the present invention is a method for identifying the serotype(s) of EHEC suspected to be present in a sample, wherein said method comprises detecting the presence or the absence, in said sample or DNA isolated therefrom, of the following *E. coli* Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) sequences:

a) CRISPRs sequences for identifying EHEC O157:[H7] wherein said CRISPRs sequences are selected among:

- the CRISPRs sequences SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3, wherein the presence of one or more of said sequences SEQ ID NO: 1-3 is indicative of the presence of EHEC O157:[H7]; and/or

- the CRISPR sequence SEQ ID NO: 4, wherein the presence of said CRISPR sequence is indicative of the presence of EHEC O157:[H7]; and

b) a CRISPR sequence for identifying EHEC O145:[H28], wherein said CRISPR sequence is the sequence SEQ ID NO: 5, and wherein the presence of said CRISPR sequence is indicative of the presence of EHEC O145:[H28]; and

c) a CRISPR sequence for identifying EHEC O111:[H8], wherein said CRISPR sequence is the sequence SEQ ID NO: 6, and wherein the presence of said CRISPR sequence is indicative of the presence of EHEC O111:[H8]; and

d) a CRISPR sequence for identifying EHEC O121:[H19], wherein said CRISPR sequence is the sequence SEQ ID NO: 7, and wherein the presence of said CRISPR sequence is indicative of the presence of EHEC O121:[H19]; and

e) a CRISPR sequence for identifying EHEC O103:[H2] and/or EHEC O45:[H2], wherein said CRISPR sequence is the sequence SEQ ID NO: 8, and wherein the presence of said CRISPR sequence is indicative of the presence of EHEC O103:[H2] and/or of EHEC O45:[H2]; and

f) a CRISPR sequence for identifying EHEC O104:[H4], wherein said CRISPR sequence is the sequence SEQ ID NO: 9, and wherein the presence of said CRISPR sequence is indicative of the presence of EHEC O104:[H4]; and

g) a CRISPR sequence for identifying EHEC O26:[H11], wherein said CRISPR sequence is the sequence SEQ ID NO: 10, and wherein the presence of said CRISPR sequence is indicative of the presence of EHEC O26:[H11].

According to a preferred embodiment of the invention, said method comprises performing a PCR assay on said sample or DNA isolated therefrom, with primers designed for amplifying said CRISPR sequences, and checking for the presence of the corresponding amplification products.

Preferably, said PCR assay is performed with a combination of primers comprising:

a) primers for detecting EHEC O157:[H7], wherein said primers consist of :
- a set of primers targeting both the CRISPR sequences SEQ ID NO: 1 and SEQ ID NO: 2, wherein said primers are defined by the following sequences:

GGGAACACAAACCGAAACACA (SEQ ID NO: 11)

CTTAGTGTGTTCCCCGCGC (SEQ ID NO: 12) and

- a set of primers targeting the CRISPR sequence SEQ ID NO: 3 wherein said primers are defined by the following sequences:

GAACACTTTGGTGACAGTTTTTGT (SEQ ID NO: 13);

CTTAGTGTGTTCCCCGCGC (SEQ ID NO: 14),

wherein the presence of an amplification product for at least one of said sets of primers is indicative of the presence of EHEC O157:[H7]; and/or :

- a set of primers targeting the CRISPR sequence SEQ ID NO: 4, wherein said primers are defined by the following sequences:

GAACACAAACCGAAACACACG (SEQ ID NO: 15)

ATAAACCGTCACCAAAACAGTG (SEQ ID NO: 16),

wherein the presence of an amplification product for said set of primers is indicative of the presence of EHEC O157:[H7]; and

b) primers for detecting EHEC O145:[H28], wherein said primers consist of:

- a set of primers targeting the CRISPR sequence SEQ ID NO: 5, wherein said primers are defined by the following sequences:

GAACCTTGAGCCCTGCCAGAA (SEQ ID NO: 17)

ACCGCGATCTTTTCCTACCTG (SEQ ID NO: 18),

wherein the presence of an amplification product for said set of primers is indicative of the presence of EHEC O145:[H28]; and

c) primers for detecting EHEC O111:[H8], wherein said primers consist of:

- a set of primers targeting the CRISPR sequence SEQ ID NO: 6, wherein said primers are defined by the following sequences:

GTGACCGCCTGTACACGC (SEQ ID NO: 19)

CGGATATTTGGGCGTAATACC (SEQ ID NO: 20)

CTGCCGCGAGTGGTTTCAC (SEQ ID NO: 21),

wherein the presence of an amplification product for at least one of primers pairs SEQ ID NO: 19 and SEQ ID NO: 20 or SEQ ID NO: 19 and SEQ ID NO: 21 is indicative of the presence of EHEC O111:[H8]; and

d) primers for detecting EHEC O121:[H19], wherein said primers consist of:

- a set of primers targeting the CRISPR sequence SEQ ID NO: 7, wherein said primers are defined by the following sequences:

CGGGGAACACTACAGGAAAGAA (SEQ ID NO: 22)

GGCGGAATACAGGACGGGTGG (SEQ ID NO: 23),

wherein the presence of an amplification product for said set of primers is indicative of the presence of EHEC O121:[H19]; and

e) primers for detecting EHEC O103:[H2] and/or EHEC O45:[H2], wherein said primers consist of:

- a set of primers targeting the CRISPR sequence SEQ ID NO: 8, wherein said primers are defined by the following sequences:

5 GAGTCTATCAGCGACACTACC (SEQ ID NO: 24)

AACCGCAGCTCGCAGCGC (SEQ ID NO: 25),

wherein the presence of an amplification product for said set of primers is indicative of the presence of EHEC O103:[H2] and/or of EHEC O45:[H2]; and

f) primers for detecting EHEC O104:[H4], wherein said primers consist of:

10 - a set of primers targeting the CRISPR sequence SEQ ID NO: 9, wherein said primers are defined by the following sequences:

GGAATCACCGAGCGCCG (SEQ ID NO: 26);

GCCTTTGCAGCGTCTTTCCGATC (SEQ ID NO: 27);

15 wherein the presence of an amplification product for said set of primers is indicative of the presence of EHEC O104:[H4]; and

g) primers for detecting EHEC O26:[H11], wherein said primers consist of:

- two sets of primers targeting the CRISPR sequence SEQ ID NO: 10, wherein the first primers set is defined by the following sequences:

20 ACAATCGTGTGTAAATTCGCGG (SEQ ID NO: 28)

GATAAACCGTGGTACGGAACA (SEQ ID NO: 29) and the second said primers set is defined by the following sequences:

TGAAACCACTCGCGGCAGAT (SEQ ID NO: 30);

ATAAACCGATCTCCTCATCCTC (SEQ ID NO: 31);

25 wherein the presence of an amplification product for at least one of the said sets of primers is indicative of the presence of EHEC O26:[H11].

In accordance to a particular embodiment, there is provided a kit for the identification of the serotype(s) of enterohemorrhagic *Escherichia coli* (EHEC), comprising the sets of primers defined above.

30 The amplification products can be detected by any appropriate method for detection of PCR products. For instance, they can be detected by means of probes derived from the respective target sequences.


Examples of preferred probes are given below:

- a probe allowing the detection of amplification products derived from SEQ ID NO: 1 and SEQ ID NO: 2, defined by the following sequence:

CGATCAATCCGAATATGAGCGGT (SEQ ID NO: 32), and a probe allowing the detection of amplification products derived from SEQ ID NO: 3, defined by the following sequence: CACTGTTTTGGTGACGGTTTATCC (SEQ ID NO: 33), and/or a probe allowing the detection of amplification products derived from SEQ ID NO: 4, defined by the following sequence:

5 ACAAAACTGTCACCAAAGTGTTTC (SEQ ID NO: 34);

- a probe allowing the detection of amplification products derived from SEQ ID NO: 5, defined by the following sequence:



TGGGGCCTCTTTTGTACCCGG (SEQ ID NO: 35);

- a probe allowing the detection of amplification products derived from SEQ ID NO: 6, defined by the following sequence:

TGTAATGGCTCACCGGTTTATCCCC (SEQ ID NO: 36);

5 - a probe allowing the detection of amplification products derived from SEQ ID NO: 7, defined by the following sequence:

TCCGCCAACGGCGACAGGGG (SEQ ID NO: 37);

- a probe allowing the detection of amplification products derived from SEQ ID NO: 8, defined by the following sequence:

10 TCGGAACGTGGCGCTATAGGTG (SEQ ID NO: 38);

- a probe allowing the detection of amplification products derived from SEQ ID NO: 9, defined by the following sequence:

CTGGGAGGCGTATCTCACGTTCCGGT (SEQ ID NO: 39);

15 - a probe allowing the detection of amplification products derived from SEQ ID NO: 10, defined by the following sequence:

TGCTGTCTATATTTGACCAGTGTTCC (SEQ ID NO: 40);

- a probe allowing the detection of amplification products derived from SEQ ID NO: 10, defined by the following sequence:

CCAGCTACCGACAGTAGTGTGTTCC (SEQ ID NO: 41);

20 According to another aspect of the present invention, it provides a method for predicting whether a sample contains typical enterohemorrhagic *Escherichia coli* (EHEC), (which are defined herein as *Escherichia coli* strains both positive for *stx* and *eae*), and/or the atypical EHEC O104:H4 that tested positive for *stx* and negative for *eae*. Typical EHEC strains include in particular EHEC O157:H7, O145:H28, O103:H2, O111:H8, O121:H19,
25 O26:H11 and O45:H2 serotypes and their non-motile derivatives.

Said method comprises the detection of the *espK* gene and of one or more of the following target genes: *espV*, *ureD*, *Z2098*, *Z1151*, *Z1153*, *Z1154*, *Z1155*, *Z1156*, and *Z6065*.

30 These *E. coli* gene targets correspond to non LEE-encoded type III effectors derived from various genomic O-islands: OI-43, OI-44, OI-50, OI-57 and OI-71.

The combinations of *espK* with one or more of *espV*, *ureD*, *Z2098*, *Z1151*, *Z1153*, *Z1154*, *Z1155*, and *Z1156*, were identified by the inventors among several combinations of putative virulence markers, as being the more predictive of typical EHEC (*stx* and *eae* positive *E. coli* strains), and in particular of the presence of EHEC strains of
35 serotypes EHEC O157:[H7], O145:[H28], O103:[H2], O111:[H8], O121:[H19], O26:[H11] or O45:[H2]. The combination of *espK* with *Z6065* is predictive of the presence of the atypical EHEC O104:H4.

Particularly preferred combinations are the following:

- *espK* with one or more of *espV*, *ureD*, *Z2098*;
- *espK* with *Z6065*;
- *espK* with one or more of *espV*, *ureD*, *Z2098* and with *Z6065*.

5 According to a particular embodiment, said method comprises performing a PCR assay on said sample or DNA isolated therefrom with a combination of primers comprising a set of primers derived from *espK* and a set of primers derived from at least one of *espV*, *ureD*, *Z2098*, *Z1151*, *Z1153*, *Z1154*, *Z1155*, *Z1156*, and *Z6065*;

10 and detecting the presence or the absence of an amplification product for each set of primers of said combination.

According to a preferred embodiment of this method, the combination of primers further comprises a set of primers derived from *stx1* and a set of primers derived from *stx2*. This allows screening samples for both the *stx* genes, as markers of STEC, and for the additional genetic markers listed above, related to priority STEC serotypes that are associated with outbreaks and sporadic cases of HC and HUS.

In contrast to the prior art methods, the method of the invention does not necessitate the detection of the *eae* gene.

Primers derived from *espK*, *espV*, *ureD*, *Z2098*, *Z1151*, *Z1153*, *Z1154*, *Z1155*, *Z1156*, *Z6065*, *stx1* or *stx2* and suitable for use in the PCR assay of the invention, as well as probes allowing the detection of the amplification products obtained with these primers, can easily be designed by one of skill in the art, on the basis of the sequences of these genes available in the databases, for instance within the annotated sequence of *Escherichia coli* O157:H7 (strain EDL933) available in GenBank under accession number AE005174.2 .

Non-limitative examples of preferred sets of primers for use in this PCR assay are given below:

- a set of primers targeting *espK*, defined by the following sequences:

GCAGRCATCAAAAGCGAAATCACACC (SEQ ID NO: 42)

TCGTTTGGTAACTGTGGCAGATACTC (SEQ ID NO: 43)

- a set of primers targeting *espV*, defined by the following sequences:

TCAGGTTCTCGTCTGATGCCGC (SEQ ID NO: 44)

CTGGTTCAGGCCTGGAGCAGTCC (SEQ ID NO: 45)

- a set of primers targeting *ureD* defined by the following sequences:

GCAATAATTGACTCTGATTGCC (SEQ ID NO: 46)

GCTGCTGCGGTAAAATTTACT (SEQ ID NO: 47)

- a set of primers targeting *Z2098*, defined by the following sequences:

CTGAAAAGAGCCAGAACGTGC (SEQ ID NO: 48)

TGCCTAAGATCATTACCCGGAC (SEQ ID NO: 49)

- a set of primers targeting *Z1153*, defined by the following sequences:

CGATCATTGTGGGCATGTTATGCC (SEQ ID NO: 50)

CCTGAATTCACACGGTGATGCG (SEQ ID NO: 51)

- a set of primers targeting *Z1154*, defined by the following sequences:

GCCTTTTATGTTCATTATTGCGGTTG (SEQ ID NO: 52)

GTATAGTTTTAGCAATACCTTCCTGC (SEQ ID NO: 53)

5 - a set of primers targeting *Z1155*, defined by the following sequences:

GATTGTGGCGATTAATGGGGG (SEQ ID NO: 54)

ACACCGATCTGGTCATTGGCG (SEQ ID NO: 55)

- a set of primers targeting *Z1156*, defined by the following sequences:

AAACGCCTTTAAAATCTGCGTCT (SEQ ID NO: 56)

10 TGCCGTGCGCACAGTCATAAG (SEQ ID NO: 57)

- a set of primers targeting *Z1151*, defined by the following sequences:

GCCCATGGCTCCACATCCTG (SEQ ID NO: 58)

CCAAAAAAGTTATGATGATTGCACTG (SEQ ID NO: 59)

- a set of primers targeting *Z6065*, defined by the following sequences:

15 GCACTGGCCCTTGTTGCTCAGGC (SEQ ID NO: 60)

GCTCTTCCAGTGAGAATGTCTTTCCGG (SEQ ID NO: 61)

- a set of primers targeting *stx1* and *stx2*, defined by the following sequences:

TTTGTYACTGTSACAGCWGAAGCYTTACG (SEQ ID NO: 62)

20 CCCAGTTCARWGTRAGRTCACRRTC (SEQ ID NO: 63)

Non-limitative examples of probes for detecting the amplification products are given below:

- a probe allowing the detection of amplification products derived from *espK*, defined by the following sequence:

25 ATTCAGATAGAAGAAGCGCGGGCCAG (SEQ ID NO: 64);

- a probe allowing the detection of amplification products derived from *espV*, defined by the following sequence:

CTTGCAACACGTTACGCTGCCGAGTATT (SEQ ID NO: 65);

- a probe allowing the detection of amplification products derived from *UreD*, defined by the following sequence:

30 TACGCTGATCACCATGCCTGGTGC (SEQ ID NO: 66);

- a probe allowing the detection of amplification products derived from *Z2098*, defined by the following sequence:

TAACTGCTATACCTCCGCGCCG (SEQ ID NO: 67);

35 - a probe allowing the detection of amplification products derived from *Z1153*, defined by the following sequence:

TGTAACACCCAGACGGTCAGCAACATG (SEQ ID NO: 68);

- a probe allowing the detection of amplification products derived from *Z1154*, defined by the following sequence:

TCACTTCCAGTTTCTGGTGATGTTTTGAT (SEQ ID NO: 69);

- a probe allowing the detection of amplification products derived from *Z1155*, defined by the following sequence:

TGGGTGAGGTTAAAATATAAAGAACGATTGC (SEQ ID NO: 70);

- a probe allowing the detection of amplification products derived from *Z1156*, defined by the following sequence:

TAAGATATTTTCTGACTTTCCGCATGCGCTT_ (SEQ ID NO: 71);

- a probe allowing the detection of amplification products derived from *Z1151*, defined by the following sequence:

AAAGAGCCAGCGCAGAGCTGACCAG_ (SEQ ID NO: 72);

- a probe allowing the detection of amplification products derived from *Z6065*, defined by the following sequence:

TTCGCTGGAAGCAGAGCCCGTGC (SEQ ID NO: 73);

- a probe allowing the detection of amplification products derived from *stx1*, defined by the following sequence:

CTGGATGATCTCAGTGGGCGTTCTTATGTAA (SEQ ID NO: 74);

- a probe allowing the detection of amplification products derived from *stx2*, defined by the following sequence:

TCGTCAGGCACTGTCTGAAACTGCTCC (SEQ ID NO: 75);

Advantageously, the invention provides a method for predicting whether a sample contains typical enterohemorrhagic *Escherichia coli* (EHEC) of at least one of EHEC O157:[H7], O145:[H28], O103:[H2], O111:[H8], O121:[H19], O26:[H11] and O45:[H2] serotypes, and further identifying the serotype(s) of said EHEC, wherein said method comprises:

- performing a PCR assay for assessing whether or not said sample comprises EHEC of at least one of O157:[H7], O145:[H28], O103:[H2], O111:[H8], O121:[H19], O26:[H11], O45:[H2] and O104:H4 serotypes, as described above, and if the results of said PCR assay are positive,
- performing a PCR assay for identifying the serotype(s) of said EHEC, as described above.

The PCR assays of the invention can be used for testing any sample of a substance potentially containing EHEC, such as food samples, water samples, soil samples, etc.

The PCR assays of the invention can be carried out using any method suitable for PCR amplification of target sequences, using any of the various natural or engineered enzymes available for this purpose. Alternative methods such as nucleic acid

sequence-based amplification (NASBA), branched DNA, strand displacement amplification or the loop-mediated isothermal amplification (LAMP) method (Compton 1991, Chang 1991, Walker et al.1992, Notomi et al., 2000) can also be used.

Particularly preferred methods are those involving real time PCR amplification as described by Ian M. Mackay in "Real-time PCR in Microbiology : from diagnosis to characterization" (2007) Caister Academic Press, Norfolk, UK.

Real time PCR, also called quantitative real time polymerase chain reaction (qPCR) or kinetic polymerase chain reaction, is used to amplify and simultaneously quantify a targeted DNA molecule. It enables both detection and quantification (as absolute number of copies or relative amount when normalized to DNA input or additional normalizing genes) of a specific sequence in a DNA sample. The procedure follows the general principle of polymerase chain reaction; its key feature is that the amplified DNA is quantified as it accumulates in the reaction in real time after each amplification cycle (Mackay 2007). Two common methods of quantification are the use of fluorescent dyes that intercalate with double-strand DNA, and modified DNA oligonucleotide probes that fluoresce when hybridized with a complementary DNA (Mackay 2007). In the present invention the inventors have shown the second of these two methods, but the other method of quantifying PCR products based upon intercalating fluorescent dyes is also within the scope of the present invention.

Non-limiting examples of suitable fluorescent labels include 6-carboxyl-fluorescein (FAM), tetrachloro-6-carboxyfluorescein (TET), 6-carboxy-X-rhodamine (ROX). Non-limitative examples of suitable quenchers for labelling dual-labelled probes include 6-carboxy-tetramethyl-rhodamine (TAMRA), DABCYL, Non-Fluorescent Quenchers such as quenchers of the Black Hole Quencher family (BHQ), or including a minor groove binder group (MGB).

Each of the PCR assays of the invention can be carried out by performing a separate PCR reaction for each target sequence to be detected (simplex PCR). However, in many cases it will be preferred to carry out multiplex PCR, allowing amplification of several target sequences in a single reaction. Advantageously, one can use a macroarray, i.e. a preformed structure such as a substrate upon which the desired DNA primers have been spotted. Such a macroarray allows the routine performance of multiplex PCR assays described herein. By way of example, one can use the GeneDisc® macroarray (Pall-GeneDisc Technology, Bruz, France) described for instance by Beutin et al. (Beutin et al.2009) which allows the simultaneous detection of multiple targets in reaction microchambers preloaded with the reagents necessary for detecting and quantifying the required targets.

In order to ensure that the results of the assay are representative of the true contents of the sample, it may also comprise a negative amplification control to ensure any

detected products are true positives and also an inhibition control to ensure that the DNA from the sample is able to be amplified and hence that no false negatives are generated.

The invention also encompasses the primer sets and the probes defined above, allowing carrying out the PCR assays of the invention, as well as kits associating these
 5 primer sets and these probes, eventually associated with reagents to perform a PCR reaction. These kits may also comprise instructions for performing said amplification reaction. The amplification products using the primers of the invention are also part of the invention.

According to a first embodiment, a kit of the invention comprises a combination of primers comprising:

- 10 - a set of primers defined by the sequences SEQ ID NO: 11 and SEQ ID NO: 12 and a set of primers defined by the sequences SEQ ID NO: 13 and SEQ ID NO: 14, and/or a set of primers defined by the sequences SEQ ID NO: 15 and SEQ ID NO: 16;
- a set of primers defined by the sequences SEQ ID NO: 17 and
 15 SEQ ID NO: 18;
- a set of primers defined by the sequences SEQ ID NO: 19, SEQ ID NO: 20, and SEQ ID NO: 21;
- a set of primers defined by the sequences SEQ ID NO: 22 and SEQ ID NO: 23;
- 20 - a set of primers defined by the sequences SEQ ID NO: 24 and SEQ ID NO: 25;
- a set of primers defined by the sequences SEQ ID NO: 26 and SEQ ID NO: 27;
- a set of primers defined by the sequences SEQ ID NO: 28 and
 25 SEQ ID NO: 29;
- a set of primers defined by the sequences SEQ ID NO: 30 and SEQ ID NO: 31;

Preferably, said kit also comprises:

- 30 - a probe allowing the detection of amplification products derived from SEQ ID NO: 1 and SEQ ID NO: 2, and a probe allowing the detection of amplification products derived from SEQ ID NO: 3, and/or a probe allowing the detection of amplification products derived from SEQ ID NO: 4, as defined above;
- a probe allowing the detection of amplification products derived from SEQ ID NO: 5, as defined above;
- 35 - a probe allowing the detection of amplification products derived from SEQ ID NO: 6, as defined above;
- a probe allowing the detection of amplification products derived from SEQ ID NO: 7, as defined above;

- a probe allowing the detection of amplification products derived from SEQ ID NO: 8, as defined above;

- a probe allowing the detection of amplification products derived from SEQ ID NO: 9, as defined above;

5 - two probes allowing the detection of amplification products derived from SEQ ID NO: 10, as defined above.

According to a second embodiment, a kit of the invention comprises:

- a set of primers derived from *espK*, and

- one or more set(s) of primers selected among: a set of primers derived from *espV*, a set of primers derived from *ureD*, a set of primers derived from Z2098, a set of primers derived from Z1151, a set of primers derived from Z1153, a set of primers derived from Z1154, a set of primers derived from Z1155, a set of primers derived from Z1156, a set of primers derived from Z6065.

Preferably, said kit also comprises a probe allowing the detection of amplification products derived from *espK*, and one or more probe(s) selected among: a probe allowing the detection of amplification products derived from *espV*, a probe allowing the detection of amplification products derived from *ureD*, or a probe allowing the detection of amplification products derived from Z2098, a probe allowing the detection of amplification products derived from Z1151, a probe allowing the detection of amplification products derived from Z1153, a probe allowing the detection of amplification products derived from Z1154, a probe allowing the detection of amplification products derived from Z1155, a probe allowing the detection of amplification products derived from Z1156, a probe allowing the detection of amplification products derived from Z6065.

The kits according to the second embodiment described above may further comprise a set of primers targeting *stx1* and a set of primers targeting *stx2*, and preferably a probe allowing the detection of amplification products derived from *stx1*, and a probe allowing the detection of amplification products derived from *stx2*.

For a better understanding of the invention and to show how the same may be carried into effect, there will now be shown by way of example only, specific embodiments, methods and processes according to the present invention.

EXAMPLE 1: IDENTIFICATION OF DNA SEQUENCES DERIVED FROM THE CRISPRS LOCI OF *E. COLI* FOR SPECIFIC IDENTIFICATION OF ENTEROHAEMORRHAGIC *E. COLI* (EHEC)

Materials and methods

35 Bacterial strains

Strains of *E. coli* (n = 955) that were investigated for their CRISPR loci by high throughput real-time PCR are reported in Table I below.

Table I: *E. coli* strains

EHEC* (n = 331)
O103:[H25] (n=6), O103:H2 (n=38), O111:H8 (n=49), O118:[H16] (n=3), O119:[H25] (n=4), O121:H19 (n=12), O123:H11, O127:H8s, O145, O145:[H28] (n=29), O156:H21, O156:H25 (n=10), O157:[H7] (n=75), O165:H25, O172:[H25], O172:H25, O172:NM, O177 (n=2), O177:[H25], O182:[H25], O26:[H11] (n=76), O3, O45:H2, O49:H16, O5 (n=8), O55, O76:H51, O84:H2, Ont:[H2], Or:H16, OX186:[H2]
EPEC (n = 344)
O100:[H25] (n=2), O102:H19, O103:H21, O103:H8, O108:H9 (n=6), O109:H25, O111, O111:B4, O111:H11, O111:H19 (n=3), O111:H2 (n=13), O111:H25 (n=2), O111:H47, O111:H9 (n=3), O113:H6 (n=2), O114:H2 (n=6), O114:H49 (n=5), O115:H38 (n=3), O117:H25, O117:H40b (n=3), O118:H5, O118:H8a (n=3), O119:[H25], O119:H2 (n=3), O119:H6 (n=4), O119:H8 (n=2), O119:H9, O119s:H2, O123/O4:H45 (n=2), O123:H25, O125:H6, O125ac:H6 (n=3), O126:H27, O126:H6, O127, O127:H19, O127:H40 (n=4), O127:H40b (n=2), O127:H6 (n=2), O128:[H2] (n=12), O128:H8, O128ac:H2, O142:H34, O142:H6 (n=3), O145:H34 (n=5), O15:H2 (n=3), O15:H11, O15:H2 (n=3), O153:H14, O156, O156:[H8] (n=7), O156:H1 (n=2), O156:H25 (n=3), O157, O157:[H45] (n=2), O157:H16 (n=5), O157:H2, O157:H26 (n=2), O157:H39, O157:H45 (n=3), O177:H26, O186:[H45], O2:[H40] (n=2), O2:H40b, O2:H8, O21:H25, O22:H7, O26:[H11] (n=38), O26:H31, O26:H34, O28:H28 (n=4), O3:H40b, O3:H5, O3:H8a (n=3), O37:H10, O4:H16, O45, O45:H7, O45:H9, O49:[H10] (n=2), O49:H-, O5:H11, O51:H49 (n=3), O55:[H51], O55:[H7] (n=26), O55:H6 (n=5), O62:H9, O63:H6 (n=2), O66:H8/8a, O69:[H2], O69:H16 (n=2), O70/O86:H2, O70:H11 (n=5), O71:H40b, O76:H41, O76:H7 (n=5), O80:[H2] (n=3), O84:[H2], O86:[H34] (n=4), O86:H11 (n=2), O86:H40, O86:H8 (n=4), O86:H8a, O88:H8a, O89:[H2], O9:H10, O88:H10, Ont:[H10], Ont:[H6], Ont:H11, Ont:H14, Ont:H2 (n=2), Ont:H21, Or:H40b, Or:H8a, Or:H9, OX177:H11 (n=2), OX177:H6
STEC** (n = 160)
O100:NM (n=2), O101:H- (n=3), O104:H7, O105:H18, O109:H-, O110:H28, O111, O111:H10, O113:H4, O115:H18 (n=2), O116:H28, O117 (n=2), O117:H7 (n=2), O118:H12 (n=3), O125, O126, O126:H8, O128ab:H2, O130:H11, O136 (n=2), O138, O139, O139:H1, O141:[H4], O141ac, O146:H21, O146:H28 (n=2), O146:H8, O147, O149:H19, O15:H16, O153:H25 (n=3), O165:H11, O168:H8, O177/H7:H41, O171:H-, O171:H2, O172:H21, O174:[H21] (n=11), O174:H2, O174:H8 (n=4), O176:H-, O178:H19, O179:H8, O181:H49, O2:H25, O2:H27, O21:H21 (n=3), O22/O83, O22:H16 (n=2), O22:H8 (n=3), O23:H15, O3, O39:H48, O40:21, O40:H8, O46:H38 (n=2), O48:H21, O5, O5:[H19], O53, O6 (n=7), O6:H10 (n=2), O6:H34 (n=2), O68:H12, O73:H18, O74:H42, O75:H8, O76, O76:H19 (n=3), O77 (n=2), O79, O79:H48, O8:H10, O8:H19 (n=6), O8:H8, O85:H11, O86, O88:H25, O91 (n=6), O91:[H21] (n=5), O91:H10 (n=3), O91:H14 (n=2), O92, O107:H-, O92, O107:H48, O96:H19, Ont:H-, Ont:H7, Or:[H16], Or:H12, Or:H29, Or:H33, Or:H4, Or:H48, OX178:H19, OX185:H28, OX187:Hbev, OX3:H-, OX3:H2, OX3:H21, OX7:H16
Apathogenic <i>E. coli</i> (n = 120)
O103 (n=2), O103:H8, O104:H7, O110, O111:H12, O111:H21, O121:[H45], O126 (n=33), O126:H11, O126:H27 (n=3), O127 (n=8), O127:H10, O127:H21, O142 (n=8), O145:H2 (n=2), O150:H8, O153:H12, O156:H33, O156:H47, O156:H56, O157 (n=5), O157:H27, O180:H-, O26:H? (n=4), O26:H21/32, O26:H32 (n=6), O26:NM, O4:H5, O41:H7, O45:H7, O55 (n=8), O55:H19, O55:H21, O6:H4, O62:H30 (n=2), O8/O104:H10, O8/O104:H45, O86 (n=6), O86/O125ac, O86:H2, O86:H27, O88, O9:K9:H12, OX183:H18

For each serotype, n=1 unless otherwise stated.

* Including EHEC derivatives as described in (Bugarel et al. 2010). ** Including atypical EHEC.

E. coli strains were divided into Shiga-toxin producing *E. coli* or STEC (n = 160), enteropathogenic *E. coli* or EPEC (n = 344), enterohaemorrhagic *E. coli* or EHEC (n = 331) and apathogenic *E. coli* (n = 120). The STEC/EHEC type was defined on the presence of *stx*- and *eae*-genes. EHEC strains were defined as harbouring both a *stx* gene (*stx1* and/or *stx2*) and *eae*, while STEC strains harboured *stx* only. STEC included *stx*-positive and *eae*-negative *E. coli* strains of serotypes O91:[H21], O113:[H21], O104:[H21], also named atypical EHEC, which are less frequently involved in hemorrhagic diseases than other EHEC, but are a frequent cause of diarrhea. *Stx*-negative derivatives of EHEC strains were designated as EHEC-like and were defined based on their *nle* gene profile, *eae* subtype and serotype as described by Bugarel et al. (2010; 2011) except for the EHEC-like strains of serotype O26:H11 which were identified based on the presence of the gene *espK* and their

allelic type 2 of the *arcA* gene (Bugarel et al., 2011). EPEC strains were defined as described by Bugarel et al. (2011). Apathogenic *E. coli* were defined as *stx*- and *eae*- negative strains.

All strains investigated in this work were identified for the *E. coli* O (LPS) and H (flagellar) antigens and have been characterized for the *stx*- and *eae*- genes as previously reported (Bugarel et al. 2010). For examination, bacteria were cultured to single colonies on Luria-Broth Plates and grown overnight at 37°C. One colony was picked-up and DNA extracted using the InstaGene matrix (Bio-Rad Laboratories, Marnes La Coquette, France) before high throughput real-time PCR testing.

DNA Sequencing

The CRISPR loci of *E. coli* strains were PCR amplified with the primers listed in Table II. The double stranded DNA sequencing of the CRISPR amplicons was performed by Eurofins MWG Operon (Courtaboeuf, France) using the sequencing primers listed in Table II.

Table II

Primer name	Forward primer and reverse primer sequences (5' – 3')	SEQ ID	Accession	Location within sequence
		NO:	Number	
CRISPR-I-F	GGTGAAGGAGYTGGCGAAGGCGTC	76	AE005174	3665412-3665435
CRISPR-I-R	CCGGTGGATTTGGATGGGTTACG	77	AE005174	3665885-3665863
CRISPR-II-F	TGTGAACCTCTCTGGCATGGAG	78	AP010953	3786919-3786940
CRISPR-II-R	TAAAGTTGGTAGATTGTGACTGGC	79	AP010953	3787672-3787649

High-throughput real-time PCR

The LightCycler® 1536 (Roche, Meylan, France) was used to perform high-throughput real-time PCR amplifications. For the PCR setup of the LightCycler® 1536 multiwell plates, the Bravo liquid dispenser automat (Agilent Technologies, Massy, France) equipped with a chiller and the PlateLoc thermal microplate sealer (Agilent Technologies) were used. The PCR reactions contained 0.5 µl sample and 1 µl master mix containing 1x RealTime ready DNA Probes master (Roche) (corresponding to 0.7x final), 300 nM each primer and 300 nM each probe (corresponding to 200 nM final each). Amplifications were performed using FAM- or HEX-labeled TaqMan® probes. Primers and probes used for PCR amplifications are listed in Table III. The LightCycler® 1536 real-time PCR system was used with the following thermal profile: 95°C for 1 min followed by 35 cycles of 95°C for 0 s (ramp: 4.8°C/s) and 60°C for 30 s (ramp: 2.5°C/s) and a final cooling step at 40°C for 30s. The software settings were Dual color hydrolysis probes/UPL probes and Master Control.

Table III

	Forward primer, reverse primer and probe sequences (5' – 3')	SEQ ID NO:	Target sequence
SP_O157_A	GAACACAAACCGAAACACACG	15	(SEQ ID NO: 4)
	ATAAACCGTCACCAAAACAGTG	16	
	[FAM]-ACAAAACTGTCACCAAGTGTC-[BHQ1]	34	
SP_O157_B	GGGAACACAAACCGAAACACA	11	(SEQ ID NO: 1 and 2)
	CTTAGTGTGTTCCCCGCGC	12	
	[HEX]-CGATCAATCCGAATATGAGCGGT-[BHQ1]	32	
SP_O157_C	GAACACTTTGGTGACAGTTTTTGT	13	(SEQ ID NO: 3)
	CTTAGTGTGTTCCCCGCGC	14	
	[HEX]-CACTGTTTTGGTGACGTTTATCC-[BHQ1]	33	
SP_O121	CGGGGAACACTACAGGAAAGAA	22	(SEQ ID NO: 7)
	GGCGGAATACAGGACGGGTGG	23	
	[HEX]-TCCGCCAACGGCGACAGGGG-[BHQ1]	37	
SP_O45	GAGTCTATCAGCGACACTACC	24	(SEQ ID NO: 8)
	AACCGCAGCTCGCAGCGC	25	
	[HEX]-TCGGAACGTGGCGCTATAGGTG-[BHQ1]	38	
SP_O145	GAACCTTGAGCCCTGCCAGAA	17	(SEQ ID NO: 5)
	ACCGCGATCTTTTCTACCTG	18	
	[HEX]-TGGGGCCTCTTTTGTACCCGG-[BHQ1]	35	
SP_O104	GGAACCTCACCGAGCGCG	26	(SEQ ID NO: 9)
	GCCTTTGCAGCGTCTTTCCGATC	27	
	[HEX]-CTGGGAGGCGTATCTCACGTTCCGT-[BHQ1]	39	
SP_O26_C	ACAATCGTGTGTAATTCGCGG	28	(SEQ ID NO:10)
	GATAAACCGTGGTACGGAACA	29	
	[HEX]-TGCTGTCTATATTCGACCAGTGTTCC-[BHQ1]	40	
SP_O26_D	TGAAACCACTCGCGGCAGAT	30	(SEQ ID NO:10)
	ATAAACCGATCTCTCATCTC	31	
	[HEX]-CCAGCTACCGACAGTAGTGTGTTCC-[BHQ1]	41	
SP_O111	GTGACCGCCTGTACACGC	19	(SEQ ID NO: 6)
	CGGATATTTGGGCGTAATACC	20	
	CTGCCGCGAGTGTTTCAC	21	
	[HEX]-TGTAATGGCTCACCGGTTTATCCCC-[BHQ1]	36	

Results

Identification of specific DNA sequences targeting the CRISPRs loci of EHEC O157:H7

Sequencing the CRISPR loci of various EHEC O157:[H7] strains has shown the polymorphism of this locus for this serotype. Sequences characteristic of the CRISPR loci of EHEC O157:[H7] strains are reported in SEQ ID NO: 1, 2, 3 and 4. Based on these sequences and the CRISPR locus of the strain EDL933 (Accession number AE005174), various real-time PCR assays were designed (SP_O157_A, SP_O157_B and SP_O157_C) for detecting EHEC O157:[H7]. The specificity and sensitivity of the assays was tested against a panel of 955 *E. coli* strains, including 75 strains of EHEC O157:[H7] (Table I). The PCR tests proved to be highly sensitive and specific for EHEC O157:[H7]. Sensitivity of the assays was ranging from 92.0% to 97.3% with only few O157:[H7] strains being not detected by each assay. The specificity of the PCR tests was high, ranging from 99.6 to 100%. The PCR assay SP_O157_B was the unique test giving cross reaction with very few strains of serogroup O55. By combining the PCR assays SP_O157_B and SP_O157_C all the 75 EHEC O157:[H7] strains were correctly detected (100% sensitivity) and only 3 isolates of serogroup O55 were cross-reacting (99.6% specificity).

Identification of specific DNA sequences targeting the CRISPR locus of EHEC O145:H28

The CRISPR locus of EHEC O145:[H28] has been characterized (SEQ ID NO: 5) by sequencing one of the two CRISPR loci identified in *E. coli*. A PCR assay (SP_O145) has been designed from this CRISPR sequence to target EHEC O145:[H28].

- 5 Among the 955 *E. coli* strains that were investigated with this PCR test, only the 29 EHEC O145:[H28] and 4 EPEC O28:H28 strains were tested positive. Sensitivity and specificity of the PCR assay SP_O145 were respectively of 100% and 99.5%.

Identification of specific DNA sequences targeting the CRISPR locus of EHEC O111:H8

- 10 Based on the sequence of the CRISPR locus of EHEC O111:H8, (SEQ ID NO: 6), a real-time PCR assay has been designed (SP_O111) to detect EHEC O111:[H8]. Investigation of 980 *E. coli* strains by the PCR assay SP_O111 gave positive results for 47 EHEC O111:[H8] out of the 49 O111:[H8] strains tested. Only one EPEC strain of serotype O45:H7 was tested positive. Sensitivity and specificity of this PCR assay were high, 95.9% and 99.9% respectively.

15 Identification of specific DNA sequences targeting the CRISPR locus of EHEC O121:H19

- The CRISPR locus of EHEC O121:[H19] has been sequenced in this study (SEQ ID NO: 7). A PCR assay (SP_O121) has been designed from this sequence to target EHEC O121:[H19]. Among the 955 *E. coli* strains tested by the PCR assay SP_O121, only one O104:H7 and the 12 EHEC O121:[H19] strains were tested positive, showing that this
20 PCR test was highly sensitive (100%) and specific (99.9%).

Identification of specific DNA sequences targeting the CRISPRs loci of EHEC O103:H2 and O45:H2

- 25 Based on the sequence determination of the CRISPR locus of EHEC O45:[H2] (SEQ ID NO: 8) and the sequence of the CRISPR locus of EHEC O103:H2, issued from strain 12009 (accession number AP010958), a PCR assay (SP_O45) has been designed and tested positive one strain of EHEC O45:H2 and all the 38 EHEC O103:H2 strains investigated in this study. Thus, the PCR assay SP_O45 has shown high sensitivity (100%) for EHEC O103:[H2] and O45:[H2]. This test has 98.6% specificity when tested on a large panel of *E. coli*, giving only minor cross-reactions with few strains of the following serotypes:
30 O118:H8, O128:[H2], O128:H8, O128:H2, O89:[H2], O46:H38, O8:H8, O142, O145:H2 and one O103 strain that tested negative for the flagella H2.

Identification of specific DNA sequences targeting the CRISPR locus of EHEC O104:H4

- The CRISPR locus of EHEC O104:[H4] has been sequenced in this study (SEQ ID NO: 9). A PCR assay (SP_O104) has been designed from this sequence to target
35 EHEC O104:[H4]. The PCR assay targeting the CRISPR locus of *E. coli* O104:H4 has been evaluated on a panel of 1303 strains of *E. coli* that included the 186 known O-serogroups and 56 H-types. This PCR assay gave positive results for the 48 O104:H4 isolates (including one

Or:H4 isolate) related to the outbreak occurring in May 2011, and to one O104:H4 clinical isolate reported in 2001. The 39 strains of *E. coli* O104 having other H-types than H4 were tested negative. The *E. coli* strains carrying a K9 capsular antigen (O8:K9:H10, O8:K9:H45, O9:K9:H1, O9:K9:H12 and O9:K9:H51) which cross react by agglutination with the sera anti-O104 tested all negative. In final, among the other *E. coli* strains that included the 186 known O-serogroups and 56 H-types, only 5 isolates belonging to serotypes O104:H2, O43:H2, O141:H2, and O174:H2 were cross reacting with the primers and probes designed in the CRISPR locus of EHEC O104:H4. Additional O174:H2, O141:H2 and O43:H2 strains were thus tested for CRISPR-O104. Three out of twelve O174:H2 tested positive, as well as 3/4 O43:H2 and 1/8 O141:H2. All together the data showed that that this PCR test was highly sensitive (100%) and specific (99.6%).

Identification of specific DNA sequences targeting the CRISPR locus of EHEC O26:H11

Sequencing the CRISPR loci of various EHEC O26:[H11] strains has shown the polymorphism of this locus for this serotype. A Sequence characteristic of the CRISPR loci of EHEC O26:[H11] is reported in SEQ ID NO: 10. Based on these sequences and the CRISPR locus of the EHEC O26:H11 strain 11368 (Accession numbers AP010953, NC_013361), two real-time PCR assays were designed (SP_O26_C, and SP_O26_D) for detecting EHEC O26:[H11]. The specificity and sensitivity of the assays was tested against a panel of 980 *E. coli* strains, including 77 strains of EHEC O26:[H11] and EHEC-like O26:[H11]. The two PCR tests proved to be sensitive and specific for EHEC O26:[H11]. Sensitivity of the SP_O26_C PCR assay was 87.0% whereas the sensitivity of SP_O26_D PCR assay was 90.9%. Only few O26:[H11] strains were not detected by each assay. The specificity of the PCR test SP_O26_C was 98.7% (12 strains cross-reacting) whereas the specificity of the PCR test SP_O26_D was 98.1% (17 strains cross-reacting). By combining the PCR assays SP_O26_C and SP_O26_D only 4 EHEC-like O26:H11 strains out of the 77 EHEC-like and EHEC O26:[H11] strains were not detected (94.8% sensitivity) and only 26 *E. coli* were cross-reacting (97.1% specificity).

Conclusion:

The results of this study are summarized in Table IV below.

Table IV: Sensitivity and specificity

Serotype	Number	PCR	Sensitivity	Specificity	Cross-reaction
O157:[H7] ^a	75	SP_O157_A	92.0%	100%	-
		SP_O157_B	97.3%	99.6%	O55:[H7] ^a , O55:[H7] (n=2) ^b
		SP_O157_C	94.7%	100%	-
		SP_O157_B+C	100%	99.6%	O55:[H7] ^a , O55:[H7] (n=2) ^b
O103:H2 ^a , O45:H2 ^a	38 1	SP_O45	100%	98.6%	O118:H8a (n=3) ^b , O128:[H2] ^b , O128:H8 ^b , O128ac:H2 ^b , O89:[H2] ^b , O46:H38 ^c , O8:H8 ^c , O103 ^d , O142 ^d , O145:H2 ^d
O111:H8 ^a	49	SP_O111	95.9%	99.9%	O45:H7 (n=1) ^b
O121:H19 ^a	12	SP_O121	100%	99.9%	O104:H7 ^d
O145:[H28] ^a	29	SP_O145	100%	99.5%	O28:H28 (n=4) ^b
O104:[H4] ^a	49	SP_O104	100%	99.6%	Ont :H2, O43:H2 (n=4), O141:H2 (n=2), and O174:H2 (n=4)
O26:[H11] ^a	77	SP_O26_C	87%	98.7%	O111:H11 ^b , O111:H47 ^b , O118:H16 (n=2) ^a , O118:H8a (n=3) ^b , O128:H8 ^b , O26:H11 ^b , O118:H2 ^a , O103:H11 ^a , O111 ^b
		SP_O26_D	90.9%	98.1%	O118:H16 (n=3) ^a , O123:H11 ^a , O26:H11 (n=9) ^b , O118:H2 (n=2) ^a , O86:H11 (n=2) ^b , O103:H11 ^a
		SP_O26_C+D	94.8%	97.1%	O111:H11 ^b , O111:H47 ^b , O118:H16 (n=4) ^a , O118:H8a (n=3) ^b , O123:H11 ^a , O128:H8 ^b , O26:H11 (n=10) ^b , O86:H11 (n=2) ^b , O118:H2 (n=2) ^a , O103:H11 ^a , O111 ^b

For each serotype, n=1 unless otherwise stated.

^a)EHEC & EHEC-like; ^b)EPEC; ^c)STEC & atypical EHEC; ^d)non pathogenic *E. coli*

- Sequencing the CRISPR loci of various EHEC strains has shown the genetic diversity of the CRISPR sequences issued from EHEC associated with the world's most frequent clinical cases. Analysis of the spacer sequences located between the short palindromic repeat sequences of the CRISPR loci, allowed identifying useful genetic markers to detect with high sensitivity and specificity EHEC strains. Based on a high-throughput real-time PCR approach, a very large panel of *E. coli* strains, that comprised EHEC, EPEC, STEC and apathogenic *E. coli* was investigated with regards to their CRISPR loci content. In final, EHEC O145:H28 (n=29), O103:H2 (n=38), O121:H19 (n=12), O104:H4 (n=49) and O45:H2 (n=1) were detected with 100% sensitivity with each PCR assays targeting various CRISPR sequences derived from these EHEC serotypes. EHEC O157:[H7] (n=75) was detected with 100% sensitivity when combining the PCR assays SP_O157_B and SP_O157_C which target two different sequences of the EHEC O157 CRISPR loci. EHEC O111:[H8] (n=49) was detected with 95.9% sensitivity (47/49 O111:[H8] were detected, only two were not detected). When combining the PCR assays SP_O26_C and SP_O26_D which target two different sequences of the O26 CRISPR loci, EHEC O26:[H11] (n=77) was detected with 94.8%

sensitivity (73/77 O26:[H11] were detected; the only 4 strains which are not detected were EHEC-like O26:H11 strains)

The PCR assays developed in this study for targeting the CRISPR loci of EHEC associated with the world's most frequent clinical cases were also highly specific. These assays had 97.1% to 100% specificity when tested on a very large panel of *E. coli* strains, giving only very minor cross-reactions (Table IV).

EXAMPLE 2: IDENTIFICATION OF GENETIC MARKERS FOR IDENTIFYING SHIGA TOXIN-PRODUCING ESCHERICHIA COLI (STEC) ASSOCIATED WITH HIGH VIRULENCE FOR HUMANS

The extended repertoire of non-LEE-encoded type III effectors (Tobe et al., 2006; Creuzburg et al., 2011) and adhesins (Spears et al., 2006; Cergole-Novella et al., 2007;) represents a most probable source of STEC virulence determinants. However, the genetic targets which support best a molecular risk assessment approach have still to be defined. Monitoring EHEC in foods requires, in particular, selection of genetic markers able to discriminate clearly EHEC from EPEC strains.

In an attempt to identify such factors, we explored the suitability of certain *nle* genes derived from the genomic O-islands OI-43, OI-44, OI-50, OI-57 and OI-71 as candidates to distinguish STEC strains constituting a severe risk for human health from EPEC and STEC strains that are not associated with severe and epidemic disease. *E. coli* gene targets used for the real-time PCR amplification are reported in Table V below.

Table V.		
Gene (ORF name if chromosomal) ^a	Encoded protein or family effector	Genetic support (mobile elements) ^a
<i>ureD</i> (Z1142, Z1581)	Urease-associated protein UreD	OI-43 & OI-48
Z1151	Hypothetical protein	OI-43
Z1153	Hypothetical protein	OI-43
Z1154	Colicin immunity protein	OI-43
Z1155	Putative membrane protein	OI-43
Z1156	Hypothetical protein	OI-43
<i>espV</i> (Z1387)	AvrA family effector	OI-44
<i>espK</i> (Z1829)	Leucine-rich repeats	OI-50
Z2098	Hypothetical protein	OI-57
Z6065	Hypothetical protein	OI-71

a) Nomenclature of ORFs and mobile elements refers to sequence of *E. coli* O157:H7 EDL933 (GenBank AE005174)

1) Genetic markers *espK*, Z1151, Z1153, Z1154, Z1155, Z1156 and Z6065.

The distribution of genetic markers derived from the OI-43 (Z1151, Z1153, Z1154, Z1155, Z1156), OI-50 (*espK*) and OI-71 (Z6065) was examined among various *E. coli* pathogroups to assess their association with STEC strains with high virulence for humans.

Materials and methods

The 1252 *E. coli* strains investigated in this study were divided into enterohaemorrhagic *E. coli* or EHEC (n = 466), enteropathogenic *E. coli* or EPEC (n = 468), Shiga-toxin producing *E. coli* or STEC (n = 179) and apathogenic *E. coli* (n = 139), based on the presence of *stx*- and *eae*-genes. STEC strains harbored *stx* only. EPEC strains harbored *eae* only. Apathogenic *E. coli* (n=139) were defined as *stx*- and *eae*- negative strains.

High throughput real-time PCR testing was performed as described in Example 1 above.

Primers and probes used for PCR amplifications of the genetic markers *espK*, *Z1151*, *Z1153*, *Z1154*, *Z1155*, *Z1156* and *Z6065* are listed in Table VI. Primers and probes for the detection of *stx1*, *stx2* and *eae*, were described previously (Bugarel et al. 2010). Amplification of the genes *stx1*, *stx2* and *eae* were used as internal controls and for group assignment purposes.

Table VI		
	Forward primer, reverse primer and probe sequences (5' – 3')	SEQ ID NO:
<i>espK</i> (1829)	GCAGRCATCAAAAGCGAAATCACACC	42
	TCGTTTGGTAACTGTGGCAGATACTC	43
	[6FAM]-ATTCAGATAGAAGAAGCGCGGGCCAG-[BHQ1]	64
<i>Z1153</i>	CGATCATTGTGGGCATGTTATGCC	50
	CCTGAATTCACACGGTGATGCG	51
	[6FAM]-TGTAACACCCAGACGGTCAGCAACATG-[BHQ1]	68
<i>Z1154</i>	GCCTTTTATGTTTATTGCGGTTG	52
	GTATAGTTTATGCAATACCTTCCTGC	53
	[6FAM]-TCACTTCCAGTTTCTGGTGATGTTTTGAT-[BHQ1]	69
<i>Z1155</i>	GATTGTGGCGATTAATGGGG	54
	ACACCGATCTGGTCATTGGCG	55
	[6FAM]-TGGGTGAGGTTAAATATAAAGAACGATTGC-[BHQ1]	70
<i>Z1156</i>	AAACGCCTTTAAATCTGCGTCT	56
	TGCCGTGCGCACAGTCATAAG	57
	[6FAM]-TAAGATATTTCTGACTTCCGCATGCGCTT-[BHQ1]	71
<i>Z1151</i>	GCCCATGGCTCCACATCCTG	58
	CCAAAAAGTTATGATGATGCACTG	59
	[6FAM]-AAAGAGCCAGCGCAGAGCTGACCAG-[BHQ1]	72
<i>Z6065</i>	GCACTGGCCCTTGTTGCTCAGGC	60
	GCTCTTCCAGTGAGAATGTCTTCCGG	61
	[6FAM]-TTCGCTGGAAGCAGAGCCCGTGC-[BHQ1]	73

Results:

Distribution of *espK*, *Z1151*, *Z1153*, *Z1154*, *Z1155*, *Z1156*, and *Z6065* and combination thereof among *E. coli* pathogroups

The distribution of the different genetic markers *espK*, *Z1151*, *Z1153*, *Z1154*, *Z1155*, *Z1156* and *Z6065* among the different *E. coli* pathogroups is shown in Table VII below. Overall, the genetic markers investigated were mostly detected in EHEC strains with frequencies ranging from 51.9% (*Z6065*) to 90.8% (*espK*). These markers were less associated with EPEC strains with frequencies ranging from 17.7% (*Z1154*) to 53.8% (*Z1155*) and rarely detected in STEC (3.4 to 20.7%) and non-pathogenic *E. coli* (3.6 to 9.4%).

None of the genetic markers *espK*, *Z1151*, *Z1153*, *Z1154*, *Z1155*, *Z1156*, and *Z6065* is, by itself, capable of reliably identifying all EHEC strains. However, when *espK* was combined with either genetic markers of the O1-43 (*Z1151*, *Z1153*, *Z1154*, *Z1155* and *Z1156*), or O1-71 (*Z6065*) most of the EHEC strains were detected with frequencies ranging from 95.5% (*espK/Z6065*) to 98.3% (*espK/Z1155*). The same combinations detected EPEC strains with frequencies ranging from 31.2% (*espK/Z1156*) to 61.8% (*espK/Z1155*), STEC strains with frequencies of 6.7% to 23.5% and non-pathogenic *E. coli* strains with frequencies between 7.9% and 13.7%.

Table VII

Genetic markers	EHEC (n=466)	EPEC (n=468)	STEC (n=179)	EC (n=139)
<i>Z1151</i>	79,8%	20,3%	20,7%	7,9%
<i>Z1153</i>	89,3%	23,9%	12,3%	9,4%
<i>Z1154</i>	83,3%	17,7%	3,4%	3,6%
<i>Z1155</i>	79,4%	53,8%	16,8%	8,6%
<i>Z1156</i>	88,8%	18,8%	12,8%	6,5%
<i>Z6065</i>	51,9%	20,1%	5,0%	8,6%
<i>espK</i>	90,8%	28,0%	3,4%	5,0%
<i>espK/Z1151</i>	97,2%	34,0%	23,5%	12,2%
<i>espK/Z1153</i>	97,4%	35,7%	15,1%	13,7%
<i>espK/Z1154</i>	97,0%	31,8%	6,7%	7,9%
<i>espK/Z1155</i>	98,3%	61,8%	19,6%	12,9%
<i>espK/Z1156</i>	97,4%	31,2%	15,6%	10,1%
<i>espK/Z6065</i>	95,5%	36,8%	8,4%	13,7%

espK/Z1151 represent strains giving a positive result for *espK* and/or *Z1151*; *espK/Z1153* represent strains giving a positive result for *espK* and/or *Z1153*; *espK/Z1154* represent strains giving a positive result for *espK* and/or *Z1154*; *espK/Z1155* represent strains giving a positive result for *espK* and/or *Z1155*; *espK/Z1156* represent strains giving a positive result for *espK* and/or *Z1156*; *espK/Z6065* represent strains giving a positive result for *espK* and/or *Z6065*

15 Distribution of the genetic markers in enterohaemorrhagic *E. coli*

The distribution of each genetic marker *espK*, *Z1151*, *Z1153*, *Z1154*, *Z1155*, *Z1156* and *Z6065* was significantly different according to EHEC serotypes (Table VIII). Interestingly, the genetic marker *Z6065* is the unique genetic marker able to detect EHEC O104:H4 (*stx* positive, *eae* negative, *aggR* positive) that has been involved in the large German outbreak in 2011.

Except *Z1151* which was not detected in any EHEC O45:[H2] and *Z6065* which was absent from 18 out of the tested 19 O121:[H19] (5.3%), all the other genetic markers investigated were found in EHEC strains of the top 7 serotypes, with frequencies ranging from 15.4% (prevalence of *Z6065* in O26:[H11]) to 100%.

By combining *espK* with one of the following genetic markers of the O1-43: *Z1151*, *Z1153*, *Z1154*, *Z1155* and *Z1156*, most of EHEC strains of top 7 EHEC serotypes were detected. Thus, whatever the combination of genetic markers used, all EHEC strains of the top 7 serotypes were tested positive, with the exception of 1 to 2 strains of EHEC O121:[H19]

which tested negative with *espK*/Z1154 and *espK*/Z6065 respectively; one strain of O103:[H2] that failed to be detected with *espK*/Z1154 and 7 to 8 strains of EHEC O26:[H11] which were found negative with all tested associations of genetic markers. Hence, only few EHEC strains did not react with the genetic markers tested here. These could be aberrant strains, not representative for the classical EHEC types. Looking at other genes in these anecdotal strains or sequencing their genome might reveal more differences which make things clearer regarding their status. We should assume, in the principle, that it is not necessarily the case that all members of a particular serotype would be EHEC.

Interestingly, other EHEC strains, with other serotypes than those of the top7 serotypes, were highly detected with frequencies ranging from 87.5% to 95.5%. This finding indicated that the tested combinations of the genetic markers could detect typical EHEC (*E. coli* strains both *stx* and *eae* positive) with high sensitivity. The introduction of the genetic marker Z6065 allows detecting in addition EHEC O104:H4 (*stx* positive, *eae* negative, *aggR* positive) that has been involved in the large German outbreak in 2011.

Table VIII

Genetic markers	O26:H11 (n=117)	O45:H2 (n=19)	O103:H2 (n=61)	O111:H8 (n=33)	O121:H1 9 (n=19)	O145:H2 8 (n=31)	O157:H7 (n=98)	Other EHEC (n=88)
Z1151	105/117 (89.7%)	0/19 (0%)	44/61 (72.1%)	33/33 (100%)	5/19 (26.3%)	30/31 (96.8%)	91/98 (92.9%)	64/88 (72.7%)
Z1153	107/117 (91.5%)	19/19 (100%)	48/61 (78.7%)	33/33 (100%)	18/19 (94.7%)	31/31 (100%)	91/98 (92.9%)	69/88 (78.4%)
Z1154	87/117 (74.4%)	19/19 (100%)	48/61 (78.7%)	31/33 (93.9%)	15/19 (78.9%)	29/31 (93.5%)	91/98 (92.9%)	68/88 (77.3%)
Z1155	75/117 64.1%	16/19 (84.2%)	41/61 (67.2%)	33/33 (100%)	14/19 (73.7%)	25/31 (80.6%)	97/98 (99.0%)	69/88 (78.4%)
Z1156	106/117 (90.6%)	19/19 (100%)	48/61 (78.7%)	33/33 (100%)	18/19 (94.7%)	31/31 (100%)	91/98 (92.9%)	68/88 (77.3%)
Z6065	18/117 (15.4%)	19/19 (100%)	59/61 (96.7%)	7/33 (21.2%)	1/19 (5.3%)	6/31 (19.4%)	85/98 (86.7%)	47/88 (53.4%)
<i>espK</i>	108/117 (92.3%)	19/19 (100%)	60/61 (98.4%)	33/33 (100%)	17/19 (89.5%)	31/31 (100%)	92/98 (93.9%)	63/88 (71.6%)
<i>espK</i> /Z1151	110/117 (94.0%)	19/19 (100%)	61/61 (100%)	33/33 (100%)	19/19 (100%)	31/31 (100%)	98/98 (100%)	82/88 (93.2%)
<i>espK</i> /Z1153	110/117 (94.0%)	19/19 (100%)	61/61 (100%)	33/33 (100%)	19/19 (100%)	31/31 (100%)	98/98 (100%)	83/88 (94.3%)
<i>espK</i> /Z1154	110/117 (94.0%)	19/19 (100%)	60/61 (98.4%)	33/33 (100%)	18/19 (94.7%)	31/31 (100%)	98/98 (100%)	83/88 (94.3%)
<i>espK</i> /Z1155	113/117 (96.6%)	19/19 (100%)	61/61 (100%)	33/33 (100%)	19/19 (100%)	31/31 (100%)	98/98 (100%)	84/88 (95.5%)
<i>espK</i> /Z1156	110/117 (94.0%)	19/19 (100%)	61/61 (100%)	33/33 (100%)	19/19 (100%)	31/31 (100%)	98/98 (100%)	83/88 (94.3%)
<i>espK</i> /Z6065	109/117 (93.2%)	19/19 (100%)	61/61 (100%)	33/33 (100%)	17/19 (89.5%)	31/31 (100%)	98/98 (100%)	77/88 (87.5%)

espK/Z1151 represent strains giving a positive result for *espK* and/or Z1151; *espK*/Z1153 represent strains giving a positive result for *espK* and/or Z1153; *espK*/Z1154 represent strains giving a positive result for *espK* and/or Z1154; *espK*/Z1155 represent strains giving a positive result for *espK* and/or Z1155; *espK*/Z1156 represent strains giving a positive result for *espK* and/or Z1156; *espK*/Z6065 represent strains giving a positive result for *espK* and/or Z6065

2) Genetic markers *espK*, *espV*, *Z2098* and *UreD*

The production of Shiga toxin (Stx) by enterohemorrhagic *E. coli* (EHEC) is the primary virulence trait responsible for Hemorrhagic colitis (HC) and Hemolytic Uremic Syndrome (HUS), but many *E. coli* strains that produce Stx (STEC) do not cause HC and HUS. Besides the ability to produce one or more types of Shiga toxins, STEC strains associated with human infections harbor other factors which might be used to distinguish STEC strains constituting a severe risk for human health from STEC strains that are not associated with severe and epidemic disease. In an attempt to identify such factors, we explored the suitability of certain *nle* genes derived from the genomic O-island OI-43, OI-44, OI-50, and OI-57 as candidates to distinguish STEC strains constituting a severe risk for human health from EPEC and STEC strains that are not associated with severe and epidemic disease. We focused on *ureD* (urease activity) encoded by OI-43 and/or OI-48, *espK* (EspK) carried by OI-50, a locus involved in persistence of EHEC O157:H7 in the intestines of orally inoculated calves (Vlisidou et al. 2006). Also, we focused on *Z2098*, a sequence derived from OI-57, a genomic island that may be associated with increased virulence of STEC strains to humans (Coombes et al., 2008; Imamovic et al, 2010; Bugarel et al., 2011). Genome sequencing of EHEC strains (EHEC O157:H7, O111, O103 and O26) has also pointed out other genetic markers, such as *espV* whose role in disease has not been evaluated. This gene is located on OI-44 of EHEC O157:H7 but its prevalence in other *E. coli* pathogroups has not been documented yet. In this study, we evaluated the distribution of *ureD*, *espV*, *espK*, and *Z2098* in various *E. coli* pathogroups to assess their association with STEC strains with high virulence for humans and to test their suitability for clearly distinguishing EHEC from other *E. coli* pathogroups.

Materials and methods

E. coli strains (n=1100) used in this study were mainly those described in the above studies. The EHEC type strains (n=340) and were defined on the presence of *stx*- and *eae*-genes. STEC strains (n=193) harbored *stx* only. EPEC strains (n=392) harbored *eae* only. Apathogenic *E. coli* (n=175) were defined as *stx*- and *eae*- negative strains. Cultivation of bacteria and preparation of DNA was performed as previously described.

High-throughput real-time PCR amplifications were also performed as described above.

Primers and FAM-labeled TaqMan® probes used for PCR amplifications of *stx1*, *stx2*, and *eae* were previously described (Bugarel al. 2010). Primers and probes used for targeting *ureD*, *espK*, *Z2098* and *espV* are listed in Table IX below.

Table IX

Target gene ^a	Forward primer, reverse primer and probe sequences (5' - 3')	SEQ ID NO:	Location within sequence AE005174
espK (Z1829)	GCAGRCATCAAAAAGCGAAATCACACC	42	1673422 – 1673397
	TCGTTTGGTAACTGTGGCAGATACTC	43	1673312 – 1673338
	[6FAM]-ATTCAGATAGAAGAAGCGCGGGCCAG-[BHQ]	64	1673395 - 16673370
espV (Z1387)	TCAGGTTCCCTCGTCTGATGCCGC	44	1295446 – 1295424
	CTGGTTCAGGCCTGGAGCAGTCC	45	1295360 – 1295382
	[6FAM]-CTTGCAACACGTTACGCTGCCGAGTATT-[BHQ]	65	1295422 - 1295395
ureD (Z1142)	GCAATAATTGACTCTGATTGCC	46	1078824 – 1078845
	GCTGCTGCGGTAAAATTACT	47	1078892 – 1078872
	[6FAM]-TACGCTGATCACCATGCCTGGTGC-[BHQ]	66	1078847 - 1078870
Z2098	CTGAAAAGAGCCAGAACGTGC	48	1888173-1888193
	TGCCTAAGATCATTACCCGGAC	49	1888308-1888287
	[HEX]TAACTGCTATACCTCCGCGCCG[BHQ]	67	1888286-1888265

a) Numbering as in EDL933

Results

Distribution of ureD, espV, espK, and Z2098 and combination thereof among E. coli pathogroups

Distribution of the genetic markers *ureD*, *espV*, *espK*, and *Z2098* among the different *E. coli* pathogroups is shown in Table X. Overall, the genetic markers investigated were mostly detected in EHEC strains with frequencies ranging from 84.4% (*espV*) to 92.4% (*espK*). These markers were less associated with EPEC strains with frequencies ranging from 18.1% (*ureD*) to 45.2% (*espV*) and rarely detected in STEC (0.5 to 3.6%) and non-pathogenic *E. coli* (0.6 to 2.9%). Overall, we observed that 26.5% of the EPEC strains which tested positive for at least one of the investigated genetic markers belonged to the top7 EHEC serotypes. Thus, it is noteworthy that 57/113 EPEC strains that are positive for *espK* belonged to the top7 EHEC serotypes. Likewise 59/177 EPEC strains positive for *espV* belonged to the top7 EHEC serotypes. It is also remarkable that 68/91 EPEC positive for *Z2098* and 58/71 EPEC strains positive for *ureD* belonged to the top7 EHEC serotypes as well. Interestingly, other EPEC strains having a known EHEC serotype such as O55:H7, O103:H25 and O156:H25 were also found positive for at least one of these genetic markers (data not shown). These findings would indicate that such isolates might be Stx-negative derivatives of EHEC that are also designated as EHEC-like strains (Bugarel et al. 2011). We assumed these isolates were EHEC-derivatives according to their serotypes and *nle* genes content but they might also be EPEC strains that we are unable to discriminate from EHEC derivatives yet. Further investigation using whole genome sequencing may clarify the exact designation of these strains in the future.

None of the genetic markers *ureD*, *espV*, *espK*, and *Z2098* is, by itself, capable of reliably identifying all EHEC strains. Combinations of the genetic markers were explored to identify those which detect EHEC with best specificity. The results are presented in Table X. In combination those genetic markers were highly associated with EHEC with frequencies ranging from 97.9% (*espK/Z2098*) to 98.8% (*espK/ureD*). The same

combinations detected EPEC strains with frequencies ranging from 33.4% (*espK/ureD*) to 54.1% (*espK/espV*), STEC strains with frequencies of 1.6% to 3.6% and non-pathogenic *E. coli* strains with frequencies between 1.1% and 3.4%.

Table X

Genetic markers	EHEC (n=340)	EPEC (n=392)	STEC (n=193)	EC (n=175)
<i>espK</i>	92.4%	28.8%	0.5%	1.1%
<i>ureD</i>	89.4%	18.1%	3.1%	2.9%
<i>Z2098</i>	87.4%	23.2%	3.6%	1.1%
<i>espV</i>	84.4%	45.2%	1.6%	0.6%
<i>espK/espV</i>	98.5%	54.1%	1.6%	1.1%
<i>espK/ureD</i>	98.8%	33.4%	3.6%	3.4%
<i>espK/Z2098</i>	97.9%	36.7%	3.6%	2.3%

- 5 *espK/espV* represent strains giving a positive result for *espK* and/or *espV*; *espK/ureD* represent strains giving a positive result for *espK* and/or *ureD*; *espK/Z2098* represent strains giving a positive result for *Z2098* and/or *espK*

Distribution of *ureD*, *espV*, *espK*, *espN*, *Z2098* and *espM1* and combination thereof among EHEC serotypes

- 10 The distribution of each genetic marker *ureD*, *espV*, *espK*, and *Z2098* was significantly different according to EHEC serotypes. Distribution of each genetic marker in various EHEC serogroups is reported in Table XI. Except *espV* which was not detected in any EHEC O45:[H2], all the other genetic markers investigated were found highly prevalent in EHEC strains of the top 7 serotypes, with frequencies ranging from 71.4% (prevalence of
- 15 *ureD* in O103:[H2]) to 100%.

Table XI.

Genetic markers	Top7 EHEC serotypes	O103:H2	O111:H8	O121:H19	O145:H28	O157:H7	O26:H11	O45:H2	Other EHEC (new emerging EHEC) ^a	Total EHEC
<i>Z2098</i>	250/277 (90.3%)	49/49 (100%)	47/51 (92.2%)	17/20 (85.0%)	30/30 (100%)	49/66 (74.2%)	44/44 (100%)	14/17 (82.4%)	47/63 (74.6%)	297/340 (87.4%)
<i>espK</i>	269/277 (97.1%)	48/49 (98.0%)	51/51 (100%)	19/20 (95.0%)	29/30 (96.7%)	61/66 (92.4%)	43/44 (97.7%)	17/17 (100%)	45/63 (71.4%)	314/340 (92.4%)
<i>espV</i>	248/277 (89.5%)	48/49 (98.0%)	51/51 (100%)	20/20 (100%)	30/30 (100%)	65/66 (98.5%)	34/44 (77.3%)	0/17 (0%)	39/63 (61.9%)	287/340 (84.4%)
<i>ureD</i>	257/277 (92.8%)	35/49 (71.4%)	51/51 (100%)	16/20 (80.0%)	30/30 (100%)	64/66 (97.0%)	44/44 (100%)	17/17 (100%)	47/63 (74.6%)	304/340 (89.4%)

- a) O103:[H25] (n=2), O118:[H16] (n=4), O118:H2, O119:[H25] (n=5), O123:H11, O127:H8s, O145, O145:[H25] (n=5), O156:H21, O156:H25 (n=11), O165:H25 (n=2), O172:[H25] (n=2), O172:NM, O177 (n=2), O177:[H25], O182:[H25], O3, O49:H16, O5 (n=11), O55:[H7] (n=2), O76:H51, O84:H2, Ont:[H2], Ont:H25 (n=2), Or:H16, OX186:[H2].
- 20

- Detection of the top 7 EHEC serotypes based on different combinations of these genetic markers is reported in Table XII. Detection of *espK* and/or *Z2098* allowed detecting most of the EHEC serotypes associated with human infections. Thus, all EHEC O111:[H8], O26:[H11], O45:[H2], O103:[H2] and O145:[H28] strains gave a positive result
- 25 for *espK* and/or *Z2098*, while 97.0% of O157:[H7] and 95 % of O121:[H19] were tested

- positive. The association of *espK* with either *espV* or *ureD* allowed detecting most of the strains of the top 7 EHEC serotypes as well. Hence, all strains of serotypes O157:[H7], O145:[H28], O111:[H8], O103:[H2], O45:[H2] and O121:[H19] gave a positive results for *espK* and/or *espV*, and 97.7% of O26:[H11] gave a positive result for *espK* and/or *espV*. Data were very similar when testing *espK* in association with *ureD*. In that case, all strains of the top7 EHEC serotypes gave a positive result for *espK* and/or *ureD*.

Table XII.

Gene association	Top7 EHEC serotypes	O103:H2	O111:H8	O121:H19	O145:H28	O157:H7	O26:H11	O45:H2	Other EHEC (new emerging EHEC) ^a	Total EHEC
<i>espK/espV</i>	276/277 (99.6%)	49/49 (100%)	51/51 (100%)	20/20 (100%)	30/30 (100%)	66/66 (100%)	43/44 (97.7%)	17/17 (100%)	59/63 (93.7%)	335/340 (98.5%)
<i>espK/ureD</i>	277/277 (100%)	49/49 (100%)	51/51 (100%)	20/20 (100%)	30/30 (100%)	66/66 (100%)	44/44 (100%)	17/17 (100%)	59/63 (93.7%)	336/340 (98.8%)
<i>espK/Z2098</i>	275/277 (99.3%)	49/49 (100%)	51/51 (100%)	19/20 (95.0%)	30/30 (100%)	65/66 (98.5%)	44/44 (100%)	17/17 (100%)	59/63 (93.7%)	334/340 (98.2%)

- a) O103:[H25] (n=2), O118:[H16] (n=4), O118:H2, O119:[H25] (n=5), O123:H11, O127:H8s, O145, O145:[H25] (n=5), O156:H21, O156:H25 (n=11), O165:H25 (n=2), O172:[H25] (n=2), O172:NM, O177 (n=2), O177:[H25], O182:[H25], O3, O49:H16, O5 (n=11), O55:[H7] (n=2), O76:H51, O84:H2, Ont:[H2], Ont:H25 (n=2), Or:H16, OX186:[H2].
espK/espV represent strains giving a positive result for *espK* and/or *espV*; *espK/ureD* represent strains giving a positive result for *espK* and/or *ureD*; *espK/Z2098* represent strains giving a positive result for Z2098 and/or *espK*

3) Summary:

- The above studies allowed selecting genetic markers Z1151, Z1153, Z1154, Z1155, Z1156, Z6065, *ureD*, *espV*, *espK* and Z2098 useful for detecting typical EHEC strains and in particular those belonging to the seven major serotypes of EHEC reported worldwide in human infections. The distribution of these different genetic markers has been investigated among the different *E. coli* pathogroups, allowing designing optimal sub-combinations of these markers. The results of these studies are summarized below.

- The genetic markers *ureD*, *espV*, *espK*, Z2098, Z1151, Z1153, Z1154, Z1155, Z1156 and Z6065 were detected at different frequencies among the EHEC serotypes. We explored the various associations of these genetic markers to search for the best combinations of markers giving the higher specificity and sensitivity for detecting EHEC. Association of the genetic marker *espK* with one of the other nine genetic markers allows detecting most of the typical EHEC strains and in particular those belonging to the top7 EHEC serotypes. The genetic markers *espV*, *ureD* and Z2098 were shown the best candidates to be combined with *espK* for detecting EHEC. Taken individually they were not able to detect all strains of the top 7 EHEC serotypes, while in association they detected 99.3% to 100% of the top 7 EHEC strains. The association of *espK* with either *espV*, *ureD* or Z2098 proved to be the best combinations for a more specific and sensitive detection of EHEC strains. Hence, a positive result for *espK* and/or *espV* was observed in 99.6% of EHEC strains belonging to the seven major serotypes of EHEC reported worldwide in human infections

(only one EHEC O26:H11 isolate tested negative). Also, 93.7% of EHEC strains with serotypes other than those of the top 7 serotypes were tested positive for *espK* and/or *espV*. In final, only a subset (54.1%) of EPEC strains tested positive for *espK* and/or *espV*. Most STEC and avirulent *E. coli* strains were found negative with both *espK* and *espV*. Another
 5 interesting approach was to associate *espK* with Z2098. This combination of genetic markers resulted in the detection of 99.3% of EHEC strains belonging to the seven major EHEC serotypes and in 93.7% of EHEC strains with serotypes other than those of the top7 serotypes. Detection of *espK* and/or Z2098 was reported for only 36.7% of EPEC, 3.6% of STEC and 2.3% of apathogenic *E. coli* strains. The best approach for detecting EHEC with the highest
 10 specificity and sensitivity was to combine *espK* with *ureD*. This association allowed detecting 100% of EHEC of the top 7 serotypes and 93.7% of EHEC strains with other serotypes. Detection of *espK* and/or *ureD* was also reported for only 33.4% of EPEC, 3.6% of STEC and 3.4% of apathogenic *E. coli* strains.

These findings showed that combining detection of *espK* with either *espV*,
 15 *ureD* or Z2098 is a highly sensitive and specific approach for identifying with $\geq 99\%$ confidence EHEC serotypes related to the world's most frequent clinical cases. Detection of these genetic markers in combination with *stx* in complex samples (food or fecal specimens) would provide a more EHEC-targeted diagnostic than that combining only *stx* and *eae*. Interestingly, introduction of Z6065 in the detection scheme allow detecting the atypical
 20 EHEC O104:H4 that was involved in the severe and largest STEC outbreak that occurred in Europe. Given the rapidity of these PCR assays, this approach should have a major impact on top7 EHEC surveillance and outbreak investigations and is likely to be of benefit to public health. Moreover, detection of these sets of genetic markers in 93.7% of EHEC strains having serotypes other than those of the top7 EHEC serotypes may be helpful to identify new
 25 emerging EHEC strains.

Conclusion

We used a high throughput PCR approach to explore the virulome of different *E. coli* pathogroups in an attempt to identify genetic traits that would characterize pathogenic STEC strains. The distribution of ten genetic markers (Z1151, Z1153, Z1154,
 30 Z1155, Z1156, Z6065, *ureD*, *espV*, *espK* and Z2098) was investigated in a large panel of *E. coli* comprising EHEC, EPEC, STEC and apathogenic *E. coli* strains. The distribution of these genetic markers varied between the *E. coli* pathogroups and according to the serotypes.

Overall, the associations of *espK* with the other nine genes (Z1151, Z1153, Z1154, Z1155, Z1156, Z6065, *ureD*, *espV*, and Z2098) were shown the best combinations for
 35 detecting EHEC strains belonging to the seven major serotypes of EHEC reported worldwide in human infections. These findings showed that using this relevant combinations of genes most of the EHEC strains were tested positive while only a subset of the EPEC strains were cross reacting. Also, only very minor STEC and avirulent *E. coli* strains cross-reacted when

using such an approach. In addition to the detection of typical EHEC strains the combination *espK/Z6065* allows detecting the atypical EHEC O104:H4 (*stx* positive, *eae* negative, *aggR* positive) that was involved in the larger epidemic of HC and HUS that occurred in Europe in 2011.

REFERENCES

- Beutin, L., S. Jahn, and P. Fach. 2009. Evaluation of the 'GeneDisc' real-time PCR system for detection of enterohaemorrhagic *Escherichia coli* (EHEC) O26, O103, O111, O145 and O157 strains according to their virulence markers and their O- and H-antigen-associated genes. J. Appl. Microbiol. 106(4): 1122-1132.
- Bugarel M, Martin A, Fach P, Beutin L. 2011. Virulence gene profiling of enterohemorrhagic (EHEC) and enteropathogenic (EPEC) *Escherichia coli* strains: a basis for molecular risk assessment of typical and atypical EPEC strains. BMC Microbiol. Jun 21;11:142.
- Bugarel M, Beutin L, Scheutz F, Loukiadis E, Fach P. 2011. Identification of genetic markers for differentiation of Shiga toxin-producing, enteropathogenic, and avirulent strains of *Escherichia coli* O26. Appl Environ Microbiol. Apr;77(7):2275-81.
- Bugarel M, Beutin L, Martin A, Gill A, Fach P. 2010. Micro-array for the identification of Shiga toxin-producing *Escherichia coli* (STEC) seropathotypes associated with Hemorrhagic Colitis and Hemolytic Uremic Syndrome in humans. Int J Food Microbiol. Sep 1;142(3):318-29.
- Bugarel M, Beutin L, Fach P. 2010. Low-density macroarray targeting non-locus of enterocyte effacement effectors (nle genes) and major virulence factors of Shiga toxin-producing *Escherichia coli* (STEC): a new approach for molecular risk assessment of STEC isolates. Appl Environ Microbiol. Jan;76(1):203-11.
- Cergole-Novella MC, Nishimura LS, Dos Santos LF, Irino K, Vaz TM, Bergamini AM, Guth BE. 2007. Distribution of virulence profiles related to new toxins and putative adhesins in Shiga toxin-producing *Escherichia coli* isolated from diverse sources in Brazil. FEMS Microbiol Lett. Sep;274(2):329-34. Epub 2007 Jul 25.
- Chang, C. 1991 "Branched DNA Amplification Multimers for the Sensitive, Direct Detection of Human Hepatitis Viruses," Nucleic Acids Symposium Series, no. 24: 197-200.
- Compton, J. 1991 "Nucleic Acid Sequence-Based Amplification," Nature 350, no. 6313: 91-92.
- Coombes BK, Wickham ME, Mascarenhas M, Gruenheid S, Finlay BB, Karmali MA. 2008. Molecular analysis as an aid to assess the public health risk of non-O157 Shiga toxin-producing *Escherichia coli* strains. Appl Environ Microbiol. Apr;74(7):2153-60.

- Creuzburg K, Middendorf B, Mellmann A, Martaler T, Holz C, Fruth A, Karch H, Schmidt H. 2011. Evolutionary analysis and distribution of type III effector genes in pathogenic *Escherichia coli* from human, animal and food sources. *Environ Microbiol.* Feb;13(2):439-52.
- 5 Frank C, Werber D, Cramer JP, Askar M, Faber M, an der Heiden M, Bernard H, Fruth A, Prager R, Spode A, Wadl M, Zoufaly A, Jordan S, Kemper MJ, Follin P, Müller L, King LA, Rosner B, Buchholz U, Stark K, Krause G; HUS Investigation Team. Epidemic profile of Shiga-toxin-producing *Escherichia coli* O104:H4 outbreak in Germany. *N Engl J Med.* 2011 Nov 10;365(19):1771-80
- 10 Gault G, Weill FX, Mariani-Kurkdjian P, Jourdan-da Silva N, King L, Aldabe B, Charron M, Ong N, Castor C, Mace M, Bingen E, Noel H, Vaillant V, Bone A, Vendrely B, Delmas Y, Combe C, Bercion R, d'Andigne E, Desjardin M, de Valk H, Rolland P. Outbreak of haemolytic uraemic syndrome and bloody diarrhoea due to *Escherichia coli* O104:H4, south-west France, June 2011. *Euro Surveill.* 2011 Jun 30;16(26).
- 15 Imamovic L, Tozzoli R, Michelacci V, Minelli F, Marziano ML, Caprioli A, Morabito S. 2010. OI-57, a genomic island of *Escherichia coli* O157, is present in other seropathotypes of Shiga toxin-producing *E. coli* associated with severe human disease. *Infect Immun.* Nov;78(11):4697-704.
- 20 Karmali, M. A., M. Mascarenhas, S. Shen, K. Ziebell, S. Johnson, R. Reid-Smith, J. Isaac-Renton, C. Clark, K. Rahn, and J. B. Kaper. 2003. Association of genomic O island 122 of *Escherichia coli* EDL 933 with verocytotoxin-producing *Escherichia coli* seropathotypes that are linked to epidemic and/or serious disease. *J. Clin. Microbiol.* 41: 4930-4940.
- Levine, M. M. 1987. *Escherichia coli* That Cause Diarrhea - Enterotoxigenic, Enteropathogenic, Enteroinvasive, Enterohemorrhagic, and Enteroadherent. *J. Infect. Dis.* 155: 377-389.
- 25 Mackay, I. 2007. Real-time PCR in Microbiology, from diagnosis to characterization. Caister Academic Press, Norfolk, UK.
- Nataro, J. P. and J. B. Kaper. 1998. Diarrheagenic *Escherichia coli*. *Clinical Microbiol. Rev.* 11: 142-201.
- 30 Notomi, T., Okayama, H., Masubuchi, H., Yonekawa, T., Watanabe, K., Amino, N., and Hase, T. 2000 Loop-Mediated Isothermal Amplification of DNA. *Nucleic Acids Research* 28, no. 12: E63.

- Scheutz F, Nielsen EM, Frimodt-Møller J, Boisen N, Morabito S, Tozzoli R, Nataro JP, Caprioli A. Characteristics of the enteroaggregative Shiga toxin/verotoxin-producing *Escherichia coli* O104:H4 strain causing the outbreak of haemolytic uraemic syndrome in Germany, May to June 2011. *Euro Surveill.* 2011 Jun 16;16(24).
- 5 Spears KJ, Roe AJ, Gally DL. 2006. A comparison of enteropathogenic and enterohaemorrhagic *Escherichia coli* pathogenesis. *FEMS Microbiol Lett.* Feb;255(2):187-202.
- Struelens MJ, Palm D, Takkinen J. Enteroaggregative, Shiga toxin-producing *Escherichia coli* O104:H4 outbreak: new microbiological findings boost coordinated investigations by
10 European public health laboratories. *Euro Surveill.* 2011 Jun 16;16(24).
- Tobe T, Beatson SA, Taniguchi H, Abe H, Bailey CM, Fivian A, Younis R, Matthews S, Marches O, Frankel G, Hayashi T, Pallen MJ. 2006. An extensive repertoire of type III secretion effectors in *Escherichia coli* O157 and the role of lambdoid phages in their dissemination. *Proc Natl Acad Sci U S A.* Oct 3;103(40):14941-6.
- 15 Vlisidou I, Marchés O, Dziva F, Mundy R, Frankel G, Stevens MP. 2006. Identification and characterization of EspK, a type III secreted effector protein of enterohaemorrhagic *Escherichia coli* O157:H7. *FEMS Microbiol Lett.* Oct;263(1):32-40.
- Walker, G., Fraiser, M., Schram, J., Little, M., Nadeau, J., and Douglas P. Malinowski, D. 1992 Strand Displacement Amplification—An Isothermal, In Vitro DNA Amplification
20 Technique, *Nucleic Acids Research* 20, no. 7: 1691–1696.

CLAIMS

1. A method for identifying the serotype(s) of enterohemorrhagic *Escherichia coli* (EHEC) suspected to be present in a sample, wherein said method comprises detecting the presence or the absence, in said sample or DNA isolated therefrom, of the following *E. coli* Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) sequences:

a) CRISPR sequences for identifying EHEC O157:[H7] wherein said CRISPR sequences are selected among

- the CRISPR sequences SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3, wherein the presence of one or more of said CRISPR SEQ ID NO: 1-3 is indicative of the presence of EHEC O157:[H7]; and/or

- the CRISPR sequence SEQ ID NO: 4, wherein the presence of said CRISPR sequence is indicative of the presence of EHEC O157:[H7];

b) a CRISPR sequence for identifying EHEC O145:[H28], wherein said CRISPR sequence is the sequence SEQ ID NO: 5, and wherein the presence of said CRISPR sequence is indicative of the presence of EHEC O145:[H28]; and

c) a CRISPR sequence for identifying EHEC O111:[H8], wherein said CRISPR sequence is the sequence SEQ ID NO: 6, and wherein the presence of said CRISPR sequence is indicative of the presence of EHEC O111:[H8]; and

d) a CRISPR sequence for identifying EHEC O121:[H19], wherein said CRISPR sequence is the sequence SEQ ID NO: 7, and wherein the presence of said CRISPR sequence is indicative of the presence of EHEC O121:[H19]; and

e) a CRISPR sequence for identifying EHEC O103:[H2] and/or EHEC O45:[H2], wherein said CRISPR sequence is the sequence SEQ ID NO: 8, and wherein the presence of said CRISPR sequence is indicative of the presence of EHEC O103:[H2] and/or of EHEC O45:[H2]; and

f) a CRISPR sequence for identifying EHEC O104:[H4], wherein said CRISPR sequence is the sequence SEQ ID NO: 9, and wherein the presence of said CRISPR sequence is indicative of the presence of EHEC O104:[H4]; and

g) a CRISPR sequence for identifying EHEC O26:[H11], wherein said CRISPR sequence is the sequence SEQ ID NO: 10, and wherein the presence of said CRISPR sequence is indicative of the presence of EHEC O26:[H11].

2. The method of claim 1, wherein said method comprises performing a PCR assay on said sample or DNA isolated therefrom with a combination of primers targeting said CRISPR sequences.

3) The method of claim 2, wherein said combination of primers comprises:

a) primers for detecting EHEC O157:[H7], wherein said primers consist of :

- a set of primers targeting both the CRISPR sequences SEQ ID NO: 1 and SEQ ID NO: 2,

5 wherein said primers are defined by the following sequences:

GGGAACACAAACCGAAACACA (SEQ ID NO: 11)

CTTAGTGTGTTCCCCGCGC (SEQ ID NO: 12) and

- a set of primers targeting the CRISPR sequence SEQ ID NO: 3 wherein said primers are defined by the following sequences:

10 GAACACTTTGGTGACAGTTTTTGT (SEQ ID NO: 13);

CTTAGTGTGTTCCCCGCGC (SEQ ID NO: 14),

wherein the presence of an amplification product for at least one of said sets of primers is indicative of the presence of EHEC O157:[H7]; and/or:

- a set of primers targeting the CRISPR sequence SEQ ID NO: 4, wherein said primers are

15 defined by the following sequences:

GAACACAAACCGAAACACACG (SEQ ID NO: 15)

ATAAACCGTCACCAAAACAGTG (SEQ ID NO: 16),

wherein the presence of an amplification product for said set of primers is indicative of the presence of EHEC O157:[H7]; and

20 b) primers for detecting EHEC O145:[H28], wherein said primers consist of:

- a set of primers targeting the CRISPR sequence SEQ ID NO: 5, wherein said primers are

defined by the following sequences:

GAACCTGAGCCCTGCCAGAA (SEQ ID NO: 17)

ACCGCGATCTTTTCTACCTG (SEQ ID NO: 18),

25 wherein the presence of an amplification product for said set of primers is indicative of the presence of EHEC O145:[H28]; and

c) primers for detecting EHEC O111:[H8], wherein said primers consist of:

- a set of primers targeting the CRISPR sequence SEQ ID NO: 6, wherein said primers are defined by the following sequences:

30 GTGACCGCCTGTACACGC (SEQ ID NO: 19)

CGGATATTGGGCGTAATACC (SEQ ID NO: 20)

CTGCCGCGAGTGGTTTCAC (SEQ ID NO: 21),

wherein the presence of an amplification product for at least one of primers pairs SEQ ID NO: 19 and SEQ ID NO: 20 or SEQ ID NO: 19 and SEQ ID NO: 21 is indicative of the presence of EHEC
35 O111:[H8]; and

d) primers for detecting EHEC O121:[H19], wherein said primers consist of:

- a set of primers targeting the CRISPR sequence SEQ ID NO: 7, wherein said primers are defined by the following sequences:

CGGGGAACACTACAGGAAAGAA (SEQ ID NO: 22)

GGCGGAATACAGGACGGGTGG (SEQ ID NO: 23),

wherein the presence of an amplification product for said set of primers is indicative of the presence of EHEC O121:[H19]; and

e) primers for detecting EHEC O103:[H2] and/or EHEC O45:[H2], wherein said primers consist of:

- a set of primers targeting the CRISPR sequence SEQ ID NO: 8, wherein said primers are defined by the following sequences:

GAGTCTATCAGCGACACTACC (SEQ ID NO: 24)

AACCGCAGCTCGCAGCGC (SEQ ID NO: 25),

wherein the presence of an amplification product for said set of primers is indicative of the presence of EHEC O103:[H2] and/or of EHEC O45:[H2]; and

f) primers for detecting EHEC O104:[H4], wherein said primers consist of:

- a set of primers targeting the CRISPR sequence SEQ ID NO: 9, wherein said primers are defined by the following sequences:

GGAACCTACCGAGCGCCG (SEQ ID NO: 26);

GCCTTTGCAGCGTCTTCCGATC (SEQ ID NO: 27);

wherein the presence of an amplification product for said set of primers is indicative of the presence of EHEC O104:[H4]; and

g) primers for detecting EHEC O26:[H11], wherein said primers consist of:

- two sets of primers targeting the CRISPR sequence SEQ ID NO: 10, wherein the first set of primers is defined by the following sequences:

ACAATCGTGTGTAAATTCGCGG (SEQ ID NO: 28)

GATAAACCGTGGTACGGAACA (SEQ ID NO: 29) and the second set of primers is defined by the following sequences:

TGAAACCACTCGCGGCAGAT (SEQ ID NO: 30);

ATAAACCGATCTCCTCATCTC (SEQ ID NO: 31);

wherein the presence of an amplification product for at least one of the said sets of primers is indicative of the presence of EHEC O26:[H11].

4) The method of any one of claims 1 to 3, which comprises a previous step for predicting whether said sample contains enterohemorrhagic *Escherichia coli* (EHEC) of at least one of EHEC O157:[H7], O145:[H28], O103:[H2], O111:[H8], O121:[H19], O26:[H11], O45:[H2] and O104:[H4] serotypes, wherein said method comprises the detection of the *espK* gene and of one or more of the following target genes: *espV*, *ureD*, *Z2098*, *Z1151*, *Z1153*, *Z1154*, *Z1155*, *Z1156*, and *Z6065*,

wherein the detection of *espK* with one or more of *espV*, *ureD*, *Z2098*, *Z1151*, *Z1153*, *Z1154*, *Z1155*, and *Z1156* is predictive of the presence of EHEC strains of serotypes EHEC O157:[H7], O145:[H28], O103:[H2], O111:[H8], O121:[H19], O26:[H11] or O45:[H2], and

the detection of *espK* with *Z6065* is predictive of the presence of the EHEC strains of serotype O104:[H4].

5. The method of claim 4, wherein said previous step for predicting whether said sample contains enterohemorrhagic *Escherichia coli* (EHEC) of at least one of EHEC O157:[H7], O145:[H28], O103:[H2], O111:[H8], O121:[H19], O26:[H11], O45:[H2] and O104:[H4] serotypes comprises the detection of the *espK* gene, at least one gene selected among *espV*, *ureD*, *Z2098*, *Z1151*, *Z1153*, *Z1154*, *Z1155*, *Z1156*, and the *Z6065* gene.

6. The method of claim 4 or 5, wherein said previous step for predicting whether said sample contains enterohemorrhagic *Escherichia coli* (EHEC) of at least one of EHEC O157:[H7], O145:[H28], O103:[H2], O111:[H8], O121:[H19], O26:[H11], O45:[H2] and O104:[H4] serotypes comprises performing a PCR assay on said sample or DNA isolated therefrom with a combination of primers comprising a set of primers targeting *espK* and a set of primers targeting at least one of *espV*, *ureD*, *Z2098*, *Z1151*, *Z1153*, *Z1154*, *Z1155*, *Z1156* and *Z6065* and detecting the presence or the absence of an amplification product for each set of primers of said combination.

7. The method of any one of claims 4 to 6, wherein said previous step for predicting whether said sample contains enterohemorrhagic *Escherichia coli* (EHEC) of at least one of EHEC O157:[H7], O145:[H28], O103:[H2], O111:[H8], O121:[H19], O26:[H11], O45:[H2] and O104:[H4] serotypes further comprises performing a PCR assay on said sample or DNA isolated therefrom with a combination of primers comprising a set of primers targeting *stx1* and a set of primers targeting *stx2* and detecting the presence or the absence of an amplification product for each set of primers of said combination.

8) A kit for the identification of the serotype(s) of enterohemorrhagic *Escherichia coli* (EHEC), comprising the sets of primers as defined in claim 3.

5 9) The kit of claim 8, further comprising a set of primers targeting *espK*, and at least one set of primers selected among: a set of primers targeting *espV*, a set of primers targeting *ureD*, a set of primers targeting Z2098, a set of primers targeting Z1151, a set of primers targeting Z1153, a set of primers targeting Z1154, a set of primers targeting Z1155, a set of primers targeting Z1156, a set of primers targeting Z6065.

10 10) The kit of claim 8 or 9, further comprising probes for detecting the amplification products for each of said set of primers.

11) The kit of any one of claims 8 to 10, further comprising a set of primers targeting *stx1* and *stx2*.

15 12) The kit of claim 11, further comprising a probe for detecting the amplification product from *stx1* and a probe for detecting the amplification product from *stx2*.